<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Claire L Shovlin, PhD, FRCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1241749106"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hereditary hemorrhagic telangiectasia (HHT; also called Osler-Weber-Rendu syndrome) is an autosomal dominant vascular disorder associated with a variety of clinical manifestations including mucocutaneous telangiectasia, epistaxis, gastrointestinal bleeding, and iron deficiency anemia. Arteriovenous malformations (AVMs) commonly occur in the pulmonary, hepatic, and cerebral circulations.</p><p>This topic review discusses the management of vascular lesions in individuals with HHT, including epistaxis; gastrointestinal lesions; and pulmonary, hepatic, and cerebral AVMs.</p><p>Other aspects of HHT care are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology, epidemiology, and diagnosis</strong> – (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for asymptomatic AVMs and testing and counseling of family members</strong> – (See  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs"</a>.)</p><p></p><p class="headingAnchor" id="H1842268103"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H3679453739"><span class="h2">Definition of terms</span><span class="headingEndMark"> — </span>The following vascular lesions are seen in individuals with HHT:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arteriovenous malformation</strong> – An arteriovenous malformation (AVM) is an abnormal vascular structure that provides a direct communication between one or more arteries and one or more veins. These may be sacs (eg, for pulmonary AVMs), small collections of intervening vessels (nidal AVMs), or direct high-flow connections between the arterial and venous side (arteriovenous fistulas [AVFs]). AVMs result in arteriovenous shunting. Shunting may also be observed secondary to dilatation of existing normal capillaries (eg, intrapulmonary shunting in the hepatopulmonary syndrome and as part of normal physiologic responses).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Telangiectasia</strong> – A telangiectasia is a small, dilated blood vessel (arteriole, venule, or capillary). The term is descriptive and refers to telangiectasia of many anatomic types and etiologies. HHT telangiectasia usually contain small arteriovenous communications and are commonly located near the surface of skin or mucous membranes.</p><p></p><p>These lesions are not specific for HHT; they can also be seen sporadically in otherwise healthy individuals, associated with other disorders, or as part of a syndrome. Additional vascular lesions are increasingly recognized, some seen more commonly in patients with HHT, and others, such as aneurysms, present at similar or only marginally increased rates to the general population.</p><p class="headingAnchor" id="H1953821663"><span class="h2">General principles of management</span><span class="headingEndMark"> — </span>Major management issues in individuals with HHT span the full range of clinical manifestations  (<a class="graphic graphic_table graphicRef74593" href="/z/d/graphic/74593.html" rel="external">table 1</a>) and have been summarized in International Guidelines published in 2020 [<a href="#rid1">1</a>] and Consensus Statements from the European Reference Network (ERN) and other groups [<a href="#rid2">2-5</a>]. </p><p>Important general elements include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient educational materials for individuals with HHT, and the location of specialized centers for diagnostic testing and management, are available from the websites of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcurehht.org%2F&amp;token=rWiM7INmmrcnF9xm6qIA0djDtHz5Nlaemfv%2BeriRPDc%3D&amp;TOPIC_ID=109902" target="_blank">Cure HHT</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvascern.eu%2Fexpertise%2Frare-diseases-wgs%2Fhht-wg%2F&amp;token=VVq4MOGhA8xc7GYzTpiZNi47aji3yU7jI3qhjgaDI%2B65yNitCixg6te3pHzT465ASOUbGTgUTkHvs358fl34aQ%3D%3D&amp;TOPIC_ID=109902" target="_blank">VASCERN</a> (the European Reference Network on Rare Multisystemic Vascular Diseases), and country-specific patient groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinician education regarding the importance of epistaxis as the main cause of anemia, the need for intervention for certain asymptomatic individuals, and the paucity of clinical signs in patients with genetically confirmed HHT with visceral AVMs [<a href="#rid6">6</a>]. HHT vascular lesions may mimic metastases to liver or lung.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with epistaxis (and less frequently, gastrointestinal bleeding) from sites that are accessible can receive dedicated local therapies; however, systemic therapies are sometimes used very successfully. (See <a class="local">'Epistaxis'</a> below and <a class="local">'Gastrointestinal lesions'</a> below and <a class="local">'Hepatic AVMs'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other localized vascular lesions should be assessed and treated  (<a class="graphic graphic_table graphicRef74593" href="/z/d/graphic/74593.html" rel="external">table 1</a>). This may require subspecialist management. The interventions used are generally the same as the treatment of the lesion in the absence of HHT. (See <a class="local">'Therapy for specific vascular lesions and iron deficiency'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic treatments may be needed for those with refractory bleeding, usually manifested by requirements for multiple blood transfusions and/or iron infusions. When reviewing evidence for systemic therapies, it is important to prioritize data from randomized trials. Individuals on the placebo arm often experience improvement in symptoms, illustrating the challenges in using observational studies to ascribe benefit [<a href="#rid7">7</a>]. (See <a class="local">'Tamoxifen and other non-guideline approaches'</a> below and <a class="local">'Bevacizumab and other systemic antiangiogenic therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When anticoagulation or antiplatelet therapy is indicated (for prophylaxis or treatment of thromboembolic or cardiovascular disease), this therapy should not be denied simply due to the HHT diagnosis. (See  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Individuals who require anticoagulation (VTE and AF)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An approach to screening for asymptomatic AVMs and other aspects of routine care are discussed separately. It is especially important to identify pulmonary AVMs (PAVMs) to prevent paradoxical emboli, strokes, and brain abscesses. (See  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs"</a>.)</p><p></p><p>Many management recommendations are based on expert opinion and observational studies; although data from randomized trials are emerging for several areas of management, randomized trials have not delivered statistical support for several proposed treatments, and larger and further studies are underway with results awaited. In the meantime, as described in the sections below, much of expert opinion and practice remains guided by observational studies [<a href="#rid1">1,3-5</a>]. The uniformity of expert opinion varies depending on the clinical situation and prevailing health care practices.</p><p>The second International HHT Guideline, published in 2020 by an international consensus group, was updated to take into account changes in evidence and advances in genetic testing [<a href="#rid1">1</a>]. The first International Guideline for the management of HHT was developed by the same group in 2006, made available online in 2007, and published in print in 2011 [<a href="#rid8">8</a>]. </p><p>The 2020 International Guideline addressed six topics: epistaxis, gastrointestinal bleeding, anemia/anticoagulation, hepatic vascular malformations, pediatrics, and pregnancy [<a href="#rid1">1</a>]. This Guideline was more nuanced in separating the severity of indications for elements of care proposed in the first Guideline (presenting in a stepwise fashion according to the severity of the disease), and also incorporated some new recommendations. </p><p class="bulletIndent1"><span class="glyph">●</span>For evaluation and therapy, the main new item in the 2020 Guideline was the incorporation of systemic antiangiogenic therapies into the algorithms for epistaxis, gastrointestinal bleeding, and severe hepatic AVMs (data on antiangiogenic therapy in HHT were not available when the first Guideline was generated in 2006). (See <a class="local">'Bevacizumab and other systemic antiangiogenic therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While previous guidelines recommended referral to specialists with relevant expertise (eg, otorhinolaryngologists, centers with neurovascular expertise), the 2020 Guideline detailed structured approaches recommended for the specialty management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia was discussed as a separate topic. Previous guidelines had discussed management with oral and intravenous iron: the 2020 Guideline included a specific recommendation for red blood cell transfusions in the settings of hemodynamic instability/shock; comorbidities that require a higher hemoglobin target; need to increase the hemoglobin acutely, such as prior to surgery or during pregnancy; and/or inability to maintain an adequate hemoglobin despite frequent iron infusions. (See <a class="local">'Iron deficiency and iron deficiency anemia'</a> below.)</p><p></p><p>Consensus statements on good practice in HHT have also been developed by the European Reference Network (ERN) on Rare Multisystemic Vascular Diseases (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvascern.eu%2F&amp;token=ct6D3Xy7Zolq4eEnnIfmLcL1sc1tfPgYoiJAYfXUyqI%3D&amp;TOPIC_ID=109902" target="_blank">VASCERN</a>). This group has identified core Outcome Measures suitable to be implemented by all clinicians evaluating a patient with HHT: PAVM screening, antibiotic prophylaxis prior to dental and surgical procedures for those with PAVMs, epistaxis advice, assessment of iron deficiency, and advice on pregnancy [<a href="#rid3">3</a>]. Subsequent manuscripts include evidence from HHT patients across the ERN [<a href="#rid3">3,4,9,10</a>]. </p><p>Frameworks published in 2022 include guidance for general health care practitioners reviewing HHT patients in non-specialty care as well as providing summary data and pathophysiological integrations for HHT specialists [<a href="#rid2">2</a>].</p><p>Educational materials for patients with HHT and the location of specialized centers for diagnostic testing and management are available from the websites of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcurehht.org%2F&amp;token=rWiM7INmmrcnF9xm6qIA0djDtHz5Nlaemfv%2BeriRPDc%3D&amp;TOPIC_ID=109902" target="_blank">Cure HHT</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvascern.eu%2Fexpertise%2Frare-diseases-wgs%2Fhht-wg%2F&amp;token=VVq4MOGhA8xc7GYzTpiZNi47aji3yU7jI3qhjgaDI%2B65yNitCixg6te3pHzT465ASOUbGTgUTkHvs358fl34aQ%3D%3D&amp;TOPIC_ID=109902" target="_blank">VASCERN</a>, and country-specific patient groups.</p><p class="headingAnchor" id="H3771788522"><span class="h1">THERAPY FOR SPECIFIC VASCULAR LESIONS AND IRON DEFICIENCY</span></p><p class="headingAnchor" id="H2058197281"><span class="h2">Epistaxis</span><span class="headingEndMark"> — </span>Epistaxis is the most common site of blood loss in HHT, affecting more than 90 percent of patients. Very high proportions experience epistaxis on a daily or near-daily basis, and the iron losses are often sufficient to cause iron deficiency anemia, even in the absence of additional gastrointestinal bleeding. Management of epistaxis and iron deficiency anemia are therefore cornerstones of HHT management. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Epistaxis'</a>.)</p><p>The 2020 International Guideline provides a stepwise approach to treatment of epistaxis, in the following sequence [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Topical therapies</p><p class="bulletIndent1"><span class="glyph">●</span>Oral <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a></p><p class="bulletIndent1"><span class="glyph">●</span>Ablative therapies by otorhinolaryngologists</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic antiangiogenic therapy (eg, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Septal dermatoplasty</p><p class="bulletIndent1"><span class="glyph">●</span>Young's procedure (nostril closure)</p><p></p><p>As discussed below, there is evidence from randomized controlled trials for <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> and <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> in HHT, and randomized trials are especially important in HHT (see <a class="local">'General principles of management'</a> above). Although tamoxifen was not addressed in the 2020 guideline, we suggest tamoxifen for individuals who require systemic therapy. Tranexamic acid is another reasonable option. (See <a class="local">'Tamoxifen and other non-guideline approaches'</a> below and <a class="local">'Oral tranexamic acid'</a> below.)</p><p>There has also been widespread adoption of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, and two further drugs (<a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a> and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>) have received European Medicine Agency orphan drug designation for use in HHT, despite not being the most commonly used agents and no supportive evidence from randomized trials. Bevacizumab can be useful for individuals with severe bleeding. However, the transiency of some responses, lack of randomized trial data, and adverse effects should also be considered. (See <a class="local">'Bevacizumab and other systemic antiangiogenic therapies'</a> below.)</p><p>The decision to use particular approaches depends on risk-benefit evaluations individualized to incorporate potential benefits and risks for the specific patient, as discussed in more detail below. Potential beneficial effects from systemic agents need to be balanced against the risks, and this is ideally conducted by clinicians with expertise using these agents in HHT. </p><p>When weighing risks and benefits, there are few randomized trials to guide care. Early randomized trials provided evidence of benefit for the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Estrogen-progesterone [<a href="#rid11">11</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">Tamoxifen</a> [<a href="#rid12">12,13</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">Tranexamic acid</a> [<a href="#rid14">14,15</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> [<a href="#rid16">16</a>]</p><p></p><p>However, other randomized trials have not shown convincing evidence of benefit in the treatment arm [<a href="#rid7">7,17-22</a>]. For two of the trials, there was marked improvement in the placebo arm, reflecting the benefit of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and gel administration [<a href="#rid17">17,18</a>].</p><p>The degree of ill health and/or compromised quality of life due to HHT-associated bleeding not responding to all other measures means that the risks of systemic therapies may be considered justifiable [<a href="#rid9">9</a>]. However, it is important to recognize that most HHT patients with nosebleeds and anemia will not require such treatments that should be reserved for severe cases. </p><p>Although all drugs have their specific side effect profiles, the risk of venous thromboembolism (VTE) requires a special note. Concerns about VTE with systemic therapies have led to the development of investigational topical agents (see <a class="local">'Topical therapies'</a> below). The systemic agents used to treat HHT-related epistaxis also increase the risk of VTE; individuals who develop VTE would require full anticoagulation with its attendant risks [<a href="#rid23">23-25</a>]. Across Europe, these agents are therefore generally avoided in patients with a prior history of VTE and/or those at particularly high risk of cerebral sequelae (eg, due to concurrent atrial fibrillation).</p><p class="headingAnchor" id="H1276840259"><span class="h3">Topical therapies</span><span class="headingEndMark"> — </span>Additional information about local therapies for the management of epistaxis is presented separately. (See  <a class="medical medical_review" href="/z/d/html/6484.html" rel="external">"Management of epistaxis in children"</a> and  <a class="medical medical_review" href="/z/d/html/265.html" rel="external">"Approach to the adult with epistaxis"</a>.)</p><p>In HHT, accumulating evidence encourages the use of local (topical) preventive therapies [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nasal humidification</p><p class="bulletIndent1"><span class="glyph">●</span>Ointments</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">Saline</a> spray [<a href="#rid17">17</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Gel [<a href="#rid18">18</a>]</p><p></p><p>These therapies are essentially free of significant adverse effects, although occasional individuals report that they seem to precipitate their nosebleeds, in which case they should be discontinued.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">Saline</a><strong> nasal sprays</strong> – Saline nasal sprays can be used to prevent drying, especially during winter and in dry environments such as airplanes. (See  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Air travel'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">Saline</a> nasal sprays demonstrated significant benefits in two trials in which they were used as placebo:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one trial from 2016 involving 80 patients with HHT randomly assigned to receive intranasal <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or a <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> nasal spray, the epistaxis severity score (ESS) in the 27 patients receiving nasal saline was reduced from 5.7 (95% CI 5.0-6.3) to 3.7 (95% CI 3.2-4.3) [<a href="#rid7">7</a>]. Other studies have demonstrated that the minimally important difference in the ESS is 0.7 [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a survey of 649 patients with HHT and epistaxis, there were positive (beneficial) scores for improvement of epistaxis with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> treatments, room humidification, and nasal lubrication [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another trial from 2016 involving 121 patients with HHT who were randomly assigned to receive one of several nasal sprays (active agents <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, estriol, <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, or <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> [placebo]), there were no significant between-group differences [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thermosensitive gel</strong> – In a randomized trial of 27 patients, benefit was seen in the placebo arm, which used a thermosensitive gel [<a href="#rid18">18</a>]. The median reduction in ESS was 1.96 (range, -0.91 to 5.98), and 9 of 12 participants (75 percent) receiving the placebo gel experienced a clinically meaningful improvement in ESS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical beta blockers</strong> – Topical betablockers have been shown to demonstrate efficacy in some but not all randomized controlled trials:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> demonstrated efficacy in a 2020 trial in 20 participants with moderate-severe HHT-related epistaxis who were randomly assigned to eight weeks of propranolol gel (1.5%) or placebo [<a href="#rid16">16</a>]. Dosing used 0.5 mL, applied to each nostril twice daily; and propranolol was continued for eight weeks in an open-label study. For the propranolol group, the ESS improved significantly (-2.03±1.7, versus -0.35±0.68 for the placebo group, p = 0.009). Hemoglobin levels also improved significantly (10.5±2.6 to 11.4±2.02 g/dL, p = 0.009); and intravenous iron and blood transfusion requirement decreased. The change in nasal endoscopy findings was not significant. During the open-label period, the ESS score improved significantly in the former placebo group (-1.99±1.41, p = 0.005). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There was not a significant benefit in a trial in which 27 participants were randomly assigned to use <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> gel or placebo gel; the median change in ESS was 2.32 (range, 0.22 to 5.97) with timolol gel versus 1.96 (-0.91 to 5.98) with placebo [<a href="#rid18">18</a>]. A clinically meaningful improvement in ESS was experienced by 9 of 11 (82 percent) in the timolol gel group versus 9 of 12 (75 percent) with placebo. In another trial that randomly assigned 58 individuals to receive timolol nasal spray (0.25 mg in each nostril twice a day for 28 consecutive days) or placebo, ESS did not improve with timolol administration [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical estrogen or other agents</strong> – A 2016 trial in which 121 patients were assigned to apply a 0.1 percent estriol ointment (a low potency metabolite of <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a>), topical <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, topical <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, or placebo to the nasal mucosa found no benefit of any of the active treatments [<a href="#rid17">17</a>]. However, the study was not sufficiently powered to rule out an effect, and a larger study of topical therapy may be warranted.</p><p></p><p class="bulletIndent1">A 2018 meta-analysis that included eight randomized placebo-controlled clinical trials found that submucosal (delivered endoscopically) <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and oral <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> delivered benefit [<a href="#rid28">28</a>]. All of the nasal sprays (bevacizumab, <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, or estrogen) showed a trend towards reduced frequency of epistaxis that did not reach statistical significance. Despite these negative findings, responses vary in different individuals, and it is not possible to predict who will respond particularly well to a given intervention.</p><p></p><p class="bulletIndent1">A 2020 randomized trial found that <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> nasal ointment, administered for six weeks, did not improve epistaxis in HHT patients after the end of the treatment [<a href="#rid20">20</a>]. </p><p></p><p>Emergency nasal packing may be required for severe hemorrhage. (See  <a class="medical medical_review" href="/z/d/html/265.html" rel="external">"Approach to the adult with epistaxis", section on 'Nasal packing'</a>.)</p><p class="headingAnchor" id="H4158700403"><span class="h3">Oral tranexamic acid</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">Tranexamic acid</a> is proposed in the 2020 HHT guidelines to be second-line therapy for HHT nosebleeds that do not respond to topical therapies. It can be taken orally two to three times per day.</p><p>Randomized trial evidence for efficacy of <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> with long-term use in HHT includes the following: </p><p class="bulletIndent1"><span class="glyph">●</span>In the 2014 ATERO trial, 118 individuals with HHT who had epistaxis for more than 60 minutes or 28 days in a month were randomly assigned to receive placebo or <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> (1.5 g orally twice per day for three months) followed by crossover to the other arm [<a href="#rid14">14</a>]. Compared with placebo, tranexamic acid was associated with a reduced duration of nosebleeds (106 versus 129 minutes per month) but no change in the number of nosebleeds (mean, 23 versus 22 per month).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized crossover trial from 2014 in which 22 patients received placebo or <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, 1 g orally three times a day for three months, also found a significant reduction in nosebleeds with tranexamic acid, although hemoglobin levels were not improved [<a href="#rid15">15</a>].</p><p></p><p>Not all experts agree with such widespread use of <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, given the generally lifelong nature of HHT nosebleeds and the possibility of side effects not captured by short-term clinical trial follow-up. In our experience, VTE has developed in patients with HHT, and ischemic strokes have occurred in patients with HHT and pulmonary AVMs (PAVMs) [<a href="#rid24">24,29</a>].</p><p><a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">Aminocaproic acid</a> is an antifibrinolytic agent with a similar mechanism of action as <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, but the published clinical experience with aminocaproic acid in HHT is much less extensive [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H443652898"><span class="h3">Ablative therapies</span><span class="headingEndMark"> — </span>For patients who continue to experience significant nosebleeds, review by an ear nose and throat (ENT) surgeon with expertise in this area is advisable to optimize interventional treatments. Dedicated local ENT treatments are generally directed to patients experiencing frequent epistaxis or less frequent massive hemorrhages [<a href="#rid31">31</a>]. In one survey, 326 of 666 unselected respondents with HHT (49 percent) required specialist invasive treatments, often requiring multimodality therapy [<a href="#rid27">27</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Different types of laser or argon plasma coagulation devices are available, with the choice of method depending on operator preference and availability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laser therapy is generally preferred over cauterization, since cauterization can damage the nasal mucosa, which may prompt vascular regrowth; however, if cauterization is the only therapy available, it can have beneficial effects [<a href="#rid27">27</a>]. In a survey comparing 267 international HHT users of cauterization and 221 users of laser therapy, laser therapy was reported to be beneficial more frequently than cauterization [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sclerotherapy is another treatment that may be effective. A randomized crossover trial involving 17 patients with HHT and epistaxis found that sclerotherapy with <a class="drug drug_general" data-topicid="10330" href="/z/d/drug information/10330.html" rel="external">sodium tetradecyl sulfate</a> resulted in a greater reduction in ESS than standard care (moisturization, cautery) [<a href="#rid32">32</a>]. A retrospective study evaluating 67 patients with HHT found that use of sclerotherapy with sodium tetradecyl sulfate resulted in similar efficacy in controlling epistaxis as laser cautery, with fewer procedures required [<a href="#rid33">33</a>]. However, the otorhinolaryngology experts within the European Reference Network (ERN) have made the point that sclerotherapy carries well-documented risks of adverse events, including blindness in the non-HHT population, and full-patient counseling seems appropriate [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coblation therapy (a term derived from the words "controlled ablation") is another treatment reported to be effective; it involves use of radiofrequency ablation at low temperatures to remove problematic tissue. In a study that followed 57 patients with HHT who underwent 150 coblation treatments over the course of 12 years, the average duration of effectiveness was 25 months (range 1 to 86 months) [<a href="#rid34">34</a>]. Of the 26 patients (46 percent) who underwent multiple coblation treatments, the overall average duration of coblation effectiveness was 16.4 months (range, 1 to72 months).</p><p></p><p class="headingAnchor" id="H2682539973"><span class="h3">Bevacizumab and other systemic antiangiogenic therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bevacizumab</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">Bevacizumab</a> is an antiangiogenic agent that inhibits vascular endothelial growth factor (VEGF). It can be very useful for individuals with severe bleeding, and antiangiogenic therapies were prominent in the recommendations from the second International HHT Guideline recommendations for epistaxis and gastrointestinal bleeding [<a href="#rid1">1</a>]. The first randomized trial did not provide clear guidance, as discussed below. Before the randomized trial, across the European Reference Network (ERN), bevacizumab was considered a choice of last resort in extremely ill individuals with compromised quality of life, based on the evidence available at the time the guideline was published, which did not include randomized trials, and the known adverse effects in HHT and other settings [<a href="#rid9">9</a>]. Further evidence to guide practice is awaited. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing</strong> – Advice on when and how to use <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> is provided in a document from the ERN [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2">This recommends a dose of 5 mg/kg body weight administered as an intravenous infusion at 14- to 21-day intervals. The initial dose should be given as a 90-minute intravenous infusion. If the first infusion is well tolerated, the second infusion may be given over 60 minutes. If the 60-minute infusion is well tolerated, all subsequent infusions may be given over 30 minutes. The recommended duration of induction treatment with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> is six infusions at 14- to 21-day intervals, resulting in 2.5 to 4 months of therapy. If bleeding is controlled after three infusions, maintenance treatment is used with an individualized schedule.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse effects</strong> – Adverse effects were evaluated in a 2019 study by the ERN on Rare Multisystemic Vascular Diseases (VASCERN) in 69 individuals with HHT who were treated with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> for a mean of 11 months for bleeding or high-output cardiac failure due to hepatic AVMs [<a href="#rid9">9</a>]. Adverse events were reported in 33 patients, more commonly in females (27 adverse events in 46 females versus 6 events in 23 males). The most common of these were joint pain (10 percent), headache (4 percent), and proteinuria (3 percent). Bleeding occurred in two patients (3 percent); one was an episode of grade 3 gastrointestinal bleeding, and one was a fatal event of catastrophic hemoptysis from a known but not monitored PAVM. This was considered possibly related to bevacizumab, as spontaneous rupture of PAVMs is highly unusual outside of pregnancy or pulmonary hypertension, which were absent in this individual. Adverse events affecting the heart valves were reported in another HHT study [<a href="#rid36">36</a>]. </p><p></p><p class="bulletIndent2">Other potential toxicities of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> identified in the general population (including cardiovascular effects [hypertension, thromboembolism, left ventricular dysfunction], non-cardiovascular effects [proteinuria, bleeding, delayed wound healing, gastrointestinal perforation, fatigue, and dysphonia], and fatal adverse events) are presented in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supporting evidence</strong> – The only randomized trial of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in HHT was a small trial that assigned 24 individuals with a high transfusion requirement (at least 4 units in the previous three months) to receive bevacizumab 5 mg/kg every 14 days for 6 infusions or placebo [<a href="#rid37">37</a>]. Individuals assigned to bevacizumab had a greater reduction in transfusions that did not reach statistical significance (64 percent of bevacizumab-treated patients reduced transfusion requirements by at least 50 percent compared with 33 percent of placebo-treated patients; p = 0.22); benefit was greatest in those with high bevacizumab concentrations (measured after the data on benefit were collected). Bevacizumab-treated patients did not have statistically significant improvements in hematologic parameters or epistaxis. Adverse events were also similar between groups. The high percentage of patients in the control group with reduced transfusion requirements serves to emphasize the fluctuating nature of bleeding in patients with HHT.</p><p></p><p class="bulletIndent2">The second International HHT Guideline reported multiple uncontrolled, retrospective series that demonstrated intravenous <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> reduced epistaxis, improved anemia, reduced transfusion requirements, or improved quality of life [<a href="#rid1">1,38-46</a>]. Further observational studies and surveys have been published since those reviewed in the Guideline [<a href="#rid47">47</a>]. </p><p></p><p class="bulletIndent2">A multicenter retrospective study from 2021 that included data from 238 individuals with HHT treated with systemic <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> found favorable safety and efficacy profiles [<a href="#rid48">48</a>]. Dosing protocols varied; the majority received four to six treatments of 5 mg/kg every two weeks, followed by maintenance treatments on a regular schedule (5 mg/kg once every 4 to 12 weeks). Responses were apparent within three months; hemoglobin levels increased by a mean of 3.2 g/dL, the mean ESS decreased by 3.4 points, and the median number of transfusions decreased from six units in six months to zero. In patients who required intravenous iron infusions, the number of infusions decreased from eight infusions in six months to two. Adverse effects included hypertension in 18 percent, fatigue in 10 percent, proteinuria in 9 percent, myalgia or arthralgia in 6 percent, and venous thromboembolism (VTE) in 2 percent (none fatal). Five percent discontinued bevacizumab for adverse events. Previous smaller studies, some from the same authors who contributed to the 2021 study above, had also suggested efficacy [<a href="#rid38">38-40,49</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IMiDs</strong> – <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> and <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> have antiangiogenic and immunomodulatory properties [<a href="#rid50">50-53</a>]. There have not been randomized controlled trials of these drugs in HHT. A 2018 systematic review of observational studies found an association between the use of low-dose thalidomide and reduced frequency and duration of epistaxis and need for transfusions [<a href="#rid54">54</a>]. Thalidomide had previously received EMA orphan drug designation for HHT [<a href="#rid55">55,56</a>]. This was based on two small series of individuals with HHT (12 and 7 patients) [<a href="#rid50">50,57</a>]. Patients reported reductions in epistaxis, but many patients (approximately two-thirds and one-third, respectively) discontinued the drug due to side effects that included drowsiness, peripheral neuropathy, nausea, and constipation. Only a minority of patients continued taking thalidomide, primarily due to these side effects [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">The safety of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> in HHT was specifically evaluated by the European Reference Network (ERN) on Rare Multisystemic Vascular Diseases (VASCERN) [<a href="#rid9">9</a>]. Sixty-seven HHT patients received thalidomide, all for bleeding, and for a mean of 13.4 months, totaling 75 person-years of treatment. Adverse events related to thalidomide were reported in 34 individuals (51 percent), with an average incidence rate of 45.3 per 100 person-years. These were seen at similar rates in males and females. They were more common in individuals with an ENG mutation than an <em>ACVRL1</em> mutation (all 17 with <em>ENG</em> versus 14 of 34 [41 percent] with <em>ACVRL1</em>). The most common reports were of peripheral neuropathy (18 percent), drowsiness (12 percent), and dizziness (9 percent). Three fatal, adverse events were possibly related to thalidomide (average incidence rate: 4 per 100 person-years).</p><p></p><p>As noted above, systemic therapies have demonstrated adverse effects of which the clinician and patient should be aware. Individuals with HHT who have a history of thromboembolic disease are excluded from clinical trials using these agents [<a href="#rid14">14,41</a>]. Clinical studies using systemic <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in HHT have also excluded individuals with cerebral arteriovenous malformations (AVMs), thrombocytopenia, or anticoagulant therapy [<a href="#rid41">41</a>]. The use of these drugs remains off-label, and reported experience is still very limited.</p><p>A number of additional antiangiogenic and other agents have appeared promising in uncontrolled studies, case reports, or preclinical models. Examples include the VEGF inhibitor <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a> and the immunosuppressive agents <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and interferon [<a href="#rid58">58-62</a>]. It has been suggested that their use should be restricted to selected, consenting individuals in randomized trials conducted at experienced HHT centers, due to the lack of evidence for benefit from randomized trials, potential side effects, and lack of long-term safety and efficacy data [<a href="#rid63">63</a>]. </p><p class="headingAnchor" id="H3519329390"><span class="h3">Further ENT options recommended in international guidelines</span><span class="headingEndMark"> — </span>Other directed therapies include septodermoplasty and/or unilateral or bilateral surgical closure of the nostrils [<a href="#rid31">31,64-69</a>]. These invasive treatments are almost always used in patients who have also received laser therapy and/or cauterization [<a href="#rid27">27,31</a>]. </p><p>Young's procedure (bilateral surgical closure of the nostrils) has not been evaluated in a randomized trial, but as published in a series of 100 cases, many seen by us in subsequent years, it can have remarkable long-term success in alleviating major nosebleeds and reversing transfusion dependency, as long as there is complete closure of nasal flow [<a href="#rid70">70</a>]. However, a small proportion of patients cannot tolerate the procedure and request reversal, and a larger number decline as they are concerned about the implication of anosmia and mouth breathing. </p><p>Some patients have been treated with submucosal injection of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> at the time of laser therapy; long-term results of this approach are awaited [<a href="#rid71">71,72</a>].</p><p class="headingAnchor" id="H3908245431"><span class="h3">Tamoxifen and other non-guideline approaches</span><span class="headingEndMark"> — </span>Additional elements that can be incorporated as part of general care include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary changes for prevention </strong>– HHT nosebleeds usually come in clusters and vary in severity over a lifetime. A proportion of people with HHT (we estimate approximately one in three) may be able to identify dietary triggers of nosebleeds that can be avoided without detrimentally impacting their lifestyle [<a href="#rid27">27,64,73</a>]. We suggest keeping a food diary of items ingested in the hours immediately prior to an unusually severe bleed to aid identification of potential precipitants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of over-the-counter supplements</strong> – Caution with over-the-counter dietary supplements offers another opportunity to avoid potential precipitants. An example is fish oil supplements, for which antiplatelet activity is not generally appreciated [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/z/d/html/5365.html" rel="external">"Fish oil: Physiologic effects and administration"</a>.)</p><p></p><p>For individuals who require systemic therapy, the 2020 International HHT Guideline discussions did not incorporate <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> (with evidence from randomized trials) and the two European Medicines Agency (EMA)-recommended drugs <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a> and <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">Tamoxifen</a> – A 2018 meta-analysis of eight randomized placebo-controlled trials demonstrated that only tamoxifen was superior to placebo, reducing both the frequency and the severity of epistaxis [<a href="#rid28">28</a>]. Tamoxifen appears to be well tolerated, has evidence of efficacy from a double-blind, randomized controlled trial, and is our first treatment of choice when a systemic agent is used for treating epistaxis. In a 2018 meta-analysis of randomized, placebo-controlled trials, tamoxifen was the only systemic agent shown to be superior to placebo; it reduced epistaxis severity and frequency [<a href="#rid28">28</a>]. Tamoxifen also has a favorable side effect profile compared with <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, and <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a> (wider HHT population use of raloxifene is awaited). However, tamoxifen would not be recommended for someone with a prior history of VTE, atrial fibrillation, or similar higher risk-factor status for venous or arterial thromboembolism. (See  <a class="medical medical_review" href="/z/d/html/764.html" rel="external">"Managing the side effects of tamoxifen and aromatase inhibitors"</a>.)</p><p></p><p class="bulletIndent1">A benefit from <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> was demonstrated in a 2009 trial that randomly assigned 25 individuals with HHT (men and women) to receive placebo or tamoxifen (20 mg daily) for six months [<a href="#rid12">12</a>]. Compared with placebo, tamoxifen was associated with a reduction in epistaxis, based on self-report and nasal endoscopy (improvement in 18 versus 90 percent). Some individuals assigned to tamoxifen also had an improvement in hemoglobin level or reduction in transfusion requirements. In an extended follow-up of patients completing the trial arm, in a total of 46 patients with mean 23.4 months of treatment, there were improvements in bleeding score, quality-of-life score, and hemoglobin concentration; none required blood transfusions [<a href="#rid13">13</a>]. These and other extended follow-up studies, as well as our experience, suggest sustained benefits from tamoxifen, and therapy has been well tolerated [<a href="#rid13">13,23,75</a>]. In contrast to other agents discussed below, we have yet to see VTE developing in HHT patients using tamoxifen [<a href="#rid23">23,75</a>].</p><p></p><p class="bulletIndent1">Premenopausal females taking <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> should be aware of the effects on other organ systems. (See  <a class="medical medical_review" href="/z/d/html/764.html" rel="external">"Managing the side effects of tamoxifen and aromatase inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">Raloxifene</a> – Raloxifene is a selective estrogen receptor modulator (SERM) that has received European Medicine Agency (EMA) orphan drug designation for HHT based on a small pilot study [<a href="#rid76">76,77</a>]. There is no evidence from randomized trials in HHT. Raloxifene is associated with an increased risk of VTE events, particularly during the first four months of treatment, and is contraindicated in people with a history of VTE, hepatic impairment, cholestasis, severe renal impairment, unexplained uterine bleeding, or endometrial cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogens</strong> – High-dose estrogens have been beneficial in the setting of gastrointestinal bleeding from AVMs (see <a class="local">'Gastrointestinal lesions'</a> below); however, we do not use high-dose estrogens due to their side effect profiles, particularly the increased risk of VTE. The 50 mg <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a> dose that was effective in one study is not tolerated by men, and we consider the risk of VTE too great to use systemic estrogens [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> – A pilot study in 43 patients suggested a possible benefit of N-acetylcysteine [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">Pazopanib</a> – A retrospective review of 13 patients who received pazopanib for transfusion-dependent anemia due to HHT bleeding reported that all 13 became transfusion independent, with evidence for reduction in ESS, decreased intravenous iron use, and improvement in hemoglobin [<a href="#rid79">79</a>]. Compared with pretreatment hemoglobin, those treated with pazopanib for 12 months had an increase in their mean hemoglobin by 4.8 g/dL (95% CI 3.6-5.9), from 7.8 to 12.7 g/dL, and decreased mean ESS by 4.77 points (95% CI 3.11-6.44 points; from 2.43 to 7.20 points). As stated by the authors, these findings require confirmation in a randomized trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral </strong><a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> – In an observational assessment of 21 patients treated with oral itraconazole, four discontinued therapy due to side effects; the remaining 17 had a decrease in mean ESS from 6.0 to 3.8 points (IQR decreased from 5.1-7.2 to 3.1-5.2) [<a href="#rid80">80</a>]. Hemoglobin levels did not change significantly.</p><p></p><p class="headingAnchor" id="H1379359022"><span class="h2">Gastrointestinal lesions</span><span class="headingEndMark"> — </span>Gastrointestinal lesions in HHT are common (seen in up to 20 percent of patients), but in the majority of cases, treatment is not required, as iron deficiency is primarily due to under-replacement of iron losses from nosebleeds. That said, a small population of patients with HHT have very severe, recurrent gastrointestinal bleeding, and some suggest this is more common in patients with <em>SMAD4</em> HHT. (See  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Individuals with SMAD4 HHT'</a>.)</p><p>Bleeding gastrointestinal lesions in HHT may be accessible for local therapies administered endoscopically. As for epistaxis, local treatments allow the patient to avoid systemic therapies with potential prothrombotic or other risks.</p><p class="bulletIndent1"><span class="glyph">●</span>Repeated endoscopic ablation of gastrointestinal lesions may be used to control bleeding in the short term  (<a class="graphic graphic_picture graphicRef79901" href="/z/d/graphic/79901.html" rel="external">picture 1</a>), although the results are not as good as in the non-HHT population [<a href="#rid81">81</a>]. Additionally, local therapies carry a potential risk of causing visceral perforations and other complications. In a 2009 guidance, repeated therapies were therefore not recommended [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Embolization and/or surgery has limited success due to recurrent disease but may be useful for emergency control of hemorrhage from discrete lesions. This is also the preferred option for diffuse or endoscopically inaccessible severe gastrointestinal bleeding.</p><p></p><p>Gastrointestinal bleeding requiring frequent endoscopic interventions, transfusions, or iron infusion may be treated with systemic agents, and additional studies are ongoing. (See <a class="local">'Bevacizumab and other systemic antiangiogenic therapies'</a> above and <a class="local">'Tamoxifen and other non-guideline approaches'</a> above.)</p><p>Additional information about management of accessible vascular lesions in the gastrointestinal tract is presented separately. (See  <a class="medical medical_review" href="/z/d/html/2557.html" rel="external">"Angiodysplasia of the gastrointestinal tract"</a> and  <a class="medical medical_review" href="/z/d/html/2576.html" rel="external">"Argon plasma coagulation in the management of gastrointestinal hemorrhage", section on 'Angiodysplasia'</a>.)</p><p>Where bleeding from an obscure source is considered (eg, due to iron deficiency anemia or a positive stool guaiac test), under-appreciated epistaxis loss is almost always the cause (see <a class="local">'Epistaxis'</a> above). The possibility of other hematologic causes of anemia should also be considered.</p><p class="headingAnchor" id="H514425074"><span class="h2">Iron deficiency and iron deficiency anemia</span><span class="headingEndMark"> — </span>Iron deficiency and iron deficiency anemia are common in individuals with HHT. The usual cause is epistaxis due to the vascular lesions of HHT. Other common non-HHT-related causes include heavy menstrual bleeding, dietary iron insufficiency, regular blood donation, pregnancy, surgery, and other traumatic events, all of which increase the requirement for iron (the hemorrhage-adjusted iron requirement [HAIR]) [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Iron deficiency'</a>.)</p><p>Most patients with iron deficiency anemia secondary to blood loss from the vascular lesions of HHT are managed conservatively by repletion of the lost iron. Evidence for responses to 35 mg elemental iron tablets (<a class="drug drug_general" data-topicid="8443" href="/z/d/drug information/8443.html" rel="external">ferrous gluconate</a>) has been published, and this is our preference for initial oral dosing for reasons described below [<a href="#rid83">83</a>]. Recommended treatment regimens for iron supplementation and education regarding supplementary ways to improve iron absorption, such as avoiding ingestion of absorption inhibitors such as tea within an hour of iron ingestion based on general population considerations, are discussed separately. If iron absorption is impaired due to concurrent inflammation or disease, and/or bleeding is severe enough, parenteral iron therapy and/or blood transfusions may be required. (See  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults"</a>.)</p><p>HHT patients have important additional considerations relative to the general population:</p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing blood losses and higher HAIR should be expected in individuals with HHT [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data indicate that treatment of anemia (together with treatment of AVMs) improves epistaxis in approximately one-third of patients with HHT [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Importantly, a smaller proportion of HHT patients (approximately 5 percent) report that iron treatments and blood transfusions make their nosebleeds worse [<a href="#rid84">84,85</a>]. We are concerned this may relate to supranormal serum iron concentrations evident in people ingesting iron tablets [<a href="#rid74">74,85</a>] and induction of endothelial injury [<a href="#rid85">85,86</a>], but this awaits clinical confirmation. Additional studies are ongoing.</p><p></p><p>Heavy menstrual bleeding is a very common problem for the female HHT population and can exacerbate iron deficiency. Heavy menstrual bleeding in patients with HHT is generally managed the same as in patients without HHT, though applying the prothrombotic concerns outlined above for systemic therapies (see <a class="local">'Bevacizumab and other systemic antiangiogenic therapies'</a> above). This information is presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p>Iron deficiency is the most common form of anemia in HHT, but as for any population, individuals may also be at risk for concurrent pathologies causing anemia, and these should be evaluated as appropriate for the patient. (See  <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p>Data from a series of HHT patients with severe anemia out of proportion to calculated hemorrhagic iron losses emphasize that low-grade hemolysis may contribute to severe anemia in HHT [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H2324314219"><span class="h2">Pulmonary AVMs</span></p><p class="headingAnchor" id="H2821069487"><span class="h3">Potential complications of PAVMs</span><span class="headingEndMark"> — </span>Pulmonary AVMs (PAVMs) are of concern in HHT because patients can develop a number of potentially life-threatening and life-changing cerebral complications including ischemic stroke caused by a paradoxical embolus to the brain and brain abscess caused by paradoxical septic emboli [<a href="#rid88">88</a>]. As noted, PAVMs affect over one-half of individuals with HHT. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Pulmonary AVMs'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoxemia versus hypoxia</strong> – PAVMs commonly cause hypoxemia (low partial pressure of oxygen [PaO<sub>2</sub>] and low hemoglobin saturation by oxygen [SaO<sub>2</sub>]) due to impaired gas exchange, though this is usually asymptomatic [<a href="#rid89">89</a>]. These changes are due to hypoxemia and not hypoxia. Individuals with HHT maintain their arterial oxygen content (CaO<sub>2</sub>), and they do not have the same physiology as patients who have low PaO<sub>2</sub>/SaO<sub>2</sub> due to parenchymal lung disease [<a href="#rid89">89</a>]. Standard recommendations for individuals with hypoxic lung disease are not applicable since individuals with hypoxemia due to right to left shunting are not specifically at risk of hypoxic pulmonary hypertension [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1">Two studies evaluating exercise capacity in individuals with HHT-associated PAVMs demonstrated that reduced exercise capacity reflects low hemoglobin and/or airflow limitation rather than hypoxemia [<a href="#rid91">91,92</a>].</p><p></p><p class="bulletIndent1">Nevertheless, it was a surprise when the evidence on how well airline flights were tolerated was published [<a href="#rid93">93</a>]. Using a retrospective questionnaire-based study, the authors examined in-flight complications and predictors in 145 HHT patients (96 with PAVMs) who reported 3950 flights, totaling 18,943 flight hours. Dyspnea and thrombotic complications were less common than expected and could not be predicted from sea-level oxygen saturations or hemoglobin concentrations (anemia) [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1">Where there are concurrent pathologies such as parenchymal lung disease or pulmonary hypertension, standard guidance should be followed; this may include supplemental oxygen in certain settings (as an example, airline flights) or continuously. Where patients with PAVMs have successfully traveled by air on many occasions when hypoxemic, and there is no change in their medical state, we do not prohibit flying, based on published evidence [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/z/d/html/2788.html" rel="external">"Assessment of adult patients for air travel"</a> and  <a class="medical medical_review" href="/z/d/html/1448.html" rel="external">"Evaluation of patients for supplemental oxygen during air travel"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Silent cerebral infarcts and stroke</strong> – Silent cerebral infarcts are also a concern; these silent infarcts have been identified on cerebral magnetic resonance images (MRIs) performed for another indication (cerebral AVM screening), emphasizing the risk in individuals with PAVMs [<a href="#rid94">94,95</a>]. In a study from the United States involving 353 individuals with HHT who had brain magnetic resonance imaging (MRI) for any reason, silent cerebral infarcts were more common in individuals with PAVMs than those without PAVMs (overall prevalence, 10 percent; with PAVMs in 81 percent of the silent infarction patients and 53 percent of the individuals without silent infarction) [<a href="#rid95">95</a>]. In a study from Europe in a group of 29 individuals with PAVMs and no history of stroke, one to five silent infarcts were found in 16 individuals (55 percent) [<a href="#rid94">94</a>]. The most frequently affected sites were the cerebellum (40 percent) and thalamus (14.3 percent), and the age-adjusted odds ratio for an infarct was 21.6 (95% CI: 3.7, 126) [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1">Septic embolism to the brain causing brain abscess is also a risk. (See  <a class="medical medical_review" href="/z/d/html/8268.html" rel="external">"Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults", section on 'Neurologic'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding</strong> – Occasionally, PAVMs may bleed; this event is rare unless PAVMs have developed a systemic arterial supply (spontaneously or post-treatment), the individual is pregnant, or the individual has pulmonary hypertension. PAVM hemorrhage may lead to hemoptysis or hemothorax.</p><p></p><p>These and other complications of PAVMs are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Pulmonary AVMs'</a> and  <a class="medical medical_review" href="/z/d/html/8268.html" rel="external">"Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults"</a>.)</p><p class="headingAnchor" id="H2932843924"><span class="h3">PAVM screening</span><span class="headingEndMark"> — </span>PAVMs are present in over one-half of individuals with HHT. Any relevant symptoms should be investigated. (See  <a class="medical medical_review" href="/z/d/html/8268.html" rel="external">"Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults", section on 'Clinical manifestations'</a>.)</p><p>The approach to screening is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'PAVM screening'</a>.)</p><p class="headingAnchor" id="H1944028644"><span class="h3">Principles of PAVM management</span><span class="headingEndMark"> — </span>Management of PAVMs should be performed by clinicians with expertise in this area and should include the following, which are in keeping with a 2017 good practice statement from the British Thoracic Society and the European Reference Network for HHT (VASCERN HHT) [<a href="#rid3">3,96</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with PAVMs should receive prophylactic antibiotics prior to dental procedures, other potentially nonsterile procedures (eg, endoscopy), and surgery, to reduce post-procedural bacteremias implicated in brain abscess pathogenesis [<a href="#rid97">97</a>]. This is one of the five VASCERN HHT Outcome Measures, where good practice is 100 percent of all PAVM patients advised in writing [<a href="#rid3">3,97</a>]. It is also important to maintain good dental care to reduce the risk of bacteremia. (See  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Antibiotic prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For PAVMs of a size amenable to embolization, embolotherapy is recommended based on evidence from observational studies that suggests reduced morbidity and mortality [<a href="#rid75">75,98-101</a>]. These data are also supported by practice standards from the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and a Cochrane database review [<a href="#rid5">5,101</a>]. Information about the details of the procedure and evidence to support its efficacy in reducing cerebral complications are presented separately. (See  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Patients suitable for embolotherapy'</a>.)</p><p></p><p class="bulletIndent1">There are occasional circumstances (eg, severe pulmonary hypertension [PH]) when risk-benefit analyses are generally <strong>not</strong> in favor of embolization or where surgery may be preferred due to a greater likelihood of complete obliteration of shunting through the lesion [<a href="#rid101">101-103</a>]. Patients with in situ metallic coils and Amplatzer vascular plugs used to treat PAVMs can safely undergo MRI [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For PAVMs that are not amenable to embolization anatomically, surgery may occasionally be warranted. While the risks of removing normal lung in an individual likely to have multiple PAVMs may in the past have outweighed the benefits, parenchymal-sparing surgical techniques mean this is less of a concern, and at our center, surgery is increasingly offered to selected patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung transplantation has been performed in very occasional cases, but in major HHT/PAVM centers, this has not been considered an option for even the majority of complicated PAVM cases, due to longevity of patients with severe hypoxemia who do not receive lung transplantation. Of five where transplantation was considered and <strong>not</strong> performed, by 2017, survival ranged from 16 to 27 (median 21) years, with surviving patients restating a preference for their ongoing medical issues [<a href="#rid105">105</a>]. Since that publication, at our institution, one patient has been referred and meets the criteria for lung transplantation; however, they are not actively transplant-listed as their quality of life is considered by the patient and the transplant team to be too high to justify the risks of lung transplantation. (See  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Surgical excision'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Experts in some countries have recommended filters to prevent paradoxical embolization of particulate material present in an intravenous solution. In other countries such as the United Kingdom, where air embolism is a "never event" (ie, one that should not occur if the available preventive measures have been implemented), insertion of such a filter is considered likely to be detrimental, compared with judicious following of safe practices for intravenous solutions [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with PAVMs are generally advised to avoid scuba diving. Having been informed of the additional risks, in our experience, some patients choose to make an informed choice of the level of risk that they would consider acceptable to them. The field is awaiting formal guidance to take into account the one in three of the general population who will also shunt through a patent foramen ovale during a dive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of complications of PAVMs (eg, ischemic stroke, brain abscess) is discussed separately. Importantly, brain abscess is often not accompanied by leukocytosis, and a low threshold for making the diagnosis should be used to ensure that there is immediate referral for neurosurgical review and that appropriate intravenous antibiotics are given [<a href="#rid75">75,107</a>]. As noted above, MRI can be performed in patients who have undergone PAVM embolization and should not be delayed in emergency situations [<a href="#rid104">104</a>]. (See  <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1279.html" rel="external">"Treatment and prognosis of bacterial brain abscess"</a>.)</p><p></p><p>Pulmonary hypertension is a separate pathology (usually, pulmonary artery [PA] pressures are low to normal in patients with PAVMs). Data from two large series published in 2017 (3176 HHT patients, pulmonary artery hypertension in &lt;2 percent) demonstrated that when pulmonary hypertension was present, it was usually part of a broader picture of hepatic AVMs, anemia, atrial fibrillation, and symptoms [<a href="#rid108">108,109</a>]. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Pulmonary hypertension'</a> and  <a class="medical medical_review" href="/z/d/html/8267.html" rel="external">"Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults"</a>.)</p><p>Additional discussion of the management of PAVMs is presented separately. (See  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations"</a>.)</p><p class="headingAnchor" id="H3247131828"><span class="h2">Hepatic AVMs</span><span class="headingEndMark"> — </span>Hepatic AVM management has been assisted by the 2020 International HHT Guidelines where the expert panel recommended the following [<a href="#rid1">1</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Screening for liver AVMs in adults with definite or suspected HHT. (See  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Hepatic AVM screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnostic testing in HHT patients with symptoms and/or signs suggestive of complicated liver AVMs (including heart failure, pulmonary hypertension, abnormal cardiac biomarkers, abnormal liver function tests, abdominal pain, portal hypertension, or encephalopathy), using Doppler ultrasound, multiphase contrast CT scan, or contrast abdominal MRI. (See <a class="local">'Identifying hepatic AVMs and determining need for treatment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Estimation of the prognosis of liver AVMs using available predictors, to identify patients in need of closer monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An intensive first-line management only for patients with complicated and/or symptomatic liver AVMs, tailored to the type of complication(s). (See <a class="local">'Initial management of hepatic AVMs'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Co-management of HHT patients with high-output cardiac failure and pulmonary hypertension by an HHT Center of Excellence and an HHT cardiologist or pulmonary hypertension specialty clinic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> is considered for patients with symptomatic high-output cardiac failure due to liver AVMs for whom first-line management is unsuccessful. For those with refractory high-output cardiac failure, biliary ischemia, or complicated portal hypertension, referral for consideration of liver transplantation is appropriate. (See <a class="local">'Role of liver transplantation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver biopsy should be <strong>avoided</strong> in any patient with proven or suspected HHT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic artery embolization be <strong>avoided</strong> in patients with liver AVMs as it is only a temporizing procedure associated with significant morbidity and mortality. </p><p></p><p class="headingAnchor" id="H683487617"><span class="h3">Identifying hepatic AVMs and determining need for treatment</span><span class="headingEndMark"> — </span>Hepatic AVMs are common in HHT, identified in approximately 50 percent of people; they are substantially more prevalent in patients with HHT2 due to pathogenic variants in <em>ACVRL1</em> [<a href="#rid110">110,111</a>]<em>.</em> Longitudinal series have shown that complications occur at an incidence of 3.6 percent per year and that 1 percent annual mortality is due to hepatic AVMs in HHT [<a href="#rid112">112</a>].</p><p>Hepatic AVMs vary in size from small telangiectasia to large AVMs and constitute three separate types of aberrant intrahepatic communications. The most common are between hepatic arteries and hepatic veins. Other types of communications include hepatic-portal shunts (between hepatic arteries and portal veins) and portohepatic shunts (between portal and hepatic veins).</p><p>Typical symptoms include reduced exercise tolerance, dyspnea, edema, ascites, and/or other consequences from high-output cardiac failure. These symptoms should prompt hepatic imaging to identify these lesions.</p><p>Despite the high prevalence of hepatic AVMs and the significant symptoms they cause, clinicians often do not suspect that the driving pathology leading to these symptoms is sited in the liver rather than the heart. Thus, diagnosis of hepatic AVMs may be delayed.</p><p>Other challenges related to identifying hepatic AVMs include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Such patients usually present to cardiologists, who may focus on a potential cardiac cause of their symptoms. Portal hypertension and its consequences including encephalopathy and varices and symptoms from mesenteric or biliary ischaemia (resulting from blood flow steal) are more likely to result in an acute picture within gastroenterology and hepatology disciplines. (See  <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">"Portal hypertension in adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms may differ according to the nature of the vascular malformations, particularly whether the portal vein is involved, and whether there is a blood flow steal through arteriovenous (AV) shunts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It may be difficult to separate out the majority of patients who will never require specific treatment of their hepatic AVMs, from the significant minority for whom the consequences of hepatic AVMs will come to dominate the clinical picture and who will require high-level specialist support that needs to be delivered in a timely fashion to intervene at the optimal time [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians may not recognize the importance of correcting anemia, atrial fibrillation, and otherwise modest cardiac pathologies to improve the clinical picture. Longitudinal studies have demonstrated that symptoms of hepatic AVMs can be exacerbated in the presence of concurrent anemia and/or atrial fibrillation [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data from two large series published in 2017 (3176 HHT patients, pulmonary artery hypertension in &lt;2 percent) demonstrated that hepatic AVMs may be accompanied by a constellation of findings including pulmonary hypertension, anemia, atrial fibrillation, and symptoms [<a href="#rid108">108,109</a>]. Hepatic AVMs (and resultant high-output cardiac states) are responsible for the most common form of pulmonary hypertension in HHT [<a href="#rid108">108,109</a>]. These data were reviewed in a consensus statement from the European Association for the Study of the Liver (EASL) and an HHT workshop held in 2017 [<a href="#rid113">113</a>]. Updated guidance from the HHT International Guidelines Committee is awaited.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For any HHT patient undergoing imaging of the liver, it is most important for clinicians to be aware of the possibility that hepatic AVMs may occur in individuals with HHT. We are aware of three cases in which hepatic AVMs were initially mistaken for cancer metastases (in one case resulting in a fatal outcome) and of two further cases where liver biopsies (performed without appreciating the presence of AVMs) resulted in catastrophic hemorrhage.</p><p></p><p class="headingAnchor" id="H3278667113"><span class="h3">Initial management of hepatic AVMs</span><span class="headingEndMark"> — </span>International consensus is that all patients with HHT should be offered screening for hepatic AVMs; however, only symptomatic hepatic AVMs should be treated [<a href="#rid114">114,115</a>]. A 2016 practice guideline from the EASL and a 2011 observational study involving 154 patients with HHT who had vascular malformations in the liver concluded that in the small proportion (approximately 8 percent) who became symptomatic, medical therapy was beneficial in most [<a href="#rid112">112,113</a>]. For most of the 39 individuals who had a clinical event related to a hepatic AVM, treatment resulted in complete response or stable disease, although eight individuals died of disease complications over the 15-year period of observation.</p><p>For those who do require treatment, therapy is individualized and should be performed by clinicians with expertise in this area. First-line treatments involve the following, as detailed in selected case series [<a href="#rid113">113,115</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of high-output heart failure, in a similar way to treatment of heart failure in non-HHT patients, with emphasis on escalating diuretics and correcting anemia [<a href="#rid112">112,113,116</a>]. Iron deficiency anemia was the precipitant of high-output cardiac failure in seven of the eight cases in the largest prospective series [<a href="#rid112">112</a>]. (See  <a class="medical medical_review" href="/z/d/html/3462.html" rel="external">"Causes and pathophysiology of high-output heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/3483.html" rel="external">"Evaluation and management of anemia and iron deficiency in adults with heart failure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of portal hypertension, in a similar way to treatment of portal hypertension in other circumstances. (See  <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">"Portal hypertension in adults", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotics in case of cholangitis. (See  <a class="medical medical_review" href="/z/d/html/658.html" rel="external">"Acute cholangitis: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p>The efficacy of these treatments are evaluated within 6 to 12 months, although earlier assessments will be required in individuals with rapid clinical deterioration [<a href="#rid113">113,115</a>].</p><p>For complicated liver AVMs that are refractory to first-line treatment, interventions directed at the hepatic arterial bed such as embolization, ligation, or banding of the hepatic artery are generally <strong>no longer advised for the majority of patients</strong> because of the high rate of complications (including potentially fatal hepatic necrosis) and up to a 20 percent acute mortality rate compared with transplantation [<a href="#rid113">113</a>]; the 10-year survival rate for transplantation is 82.5 percent [<a href="#rid117">117</a>].</p><p>Options for severe patients not responding to therapy include <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and liver transplantation. (See <a class="local">'Role of bevacizumab for liver AVMs'</a> below and <a class="local">'Role of liver transplantation'</a> below.)</p><p class="headingAnchor" id="H3914800615"><span class="h3">Role of bevacizumab for liver AVMs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">Bevacizumab</a> has observational studies of efficacy and is a first-line choice in many HHT centers in the United States. However, earlier suggestions that this reversed the need for liver transplantation have not been supported by longer-term follow-up studies in those individuals. </p><p><a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">Bevacizumab</a> is usually reserved for individuals with severe liver disease for which management is ineffective and in many countries where liver transplantation is not possible. It is proposed for older patients (over age 65) who will not meet transplantation criteria (and for patients younger than 65 years who are not medically fit for transplantation) as a "bridge to transplantation" if patients experience a response [<a href="#rid115">115</a>].</p><p>The efficacy of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in the setting of severe hepatic AVMs was demonstrated in a series of individuals with HHT who had hepatic AVMs and increased cardiac output [<a href="#rid41">41</a>]. Bevacizumab (5 mg/kg intravenously once every 14 days for a total of six doses) was associated with an improvement in cardiac index in 20 of 24 evaluable patients (83 percent); this included cardiac output normalization in five individuals and improvement in 15 others. Additional benefits included resolution of pulmonary hypertension in five of eight (63 percent) and improvement in epistaxis. Case reports and observational studies have also described improvements (in some cases dramatic) in disease manifestations attributable to hepatic AVMs (and pancreatic AVMs) with bevacizumab [<a href="#rid41">41,113,118-120</a>]. Benefits from continued use have been published [<a href="#rid121">121</a>].</p><p>Notably, the reported follow-up for these patients has been relatively short compared with the decades-long follow-up post-liver transplantation discussed below (see <a class="local">'Role of liver transplantation'</a> below). Thrombotic complications of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> have been reported in individuals with HHT [<a href="#rid122">122</a>]. These and other safety concerns such as those observed in a study from the European Reference Network (ERN) on Rare Multisystemic Vascular Diseases (VASCERN) are discussed above. (See <a class="local">'Bevacizumab and other systemic antiangiogenic therapies'</a> above.)</p><p class="headingAnchor" id="H2867854660"><span class="h3">Role of liver transplantation</span><span class="headingEndMark"> — </span>Liver transplantation in countries where very good long-term survival of HHT patients is reported can be lifesaving for those who develop acute hepatic failure (eg, acute biliary necrosis syndrome), intractable heart failure, or portal hypertension [<a href="#rid117">117,123-125</a>]. </p><p>Available data suggest that liver transplantation should be proposed in a timely fashion, before pulmonary resistances become fixed, and taking into account that complicated liver AVMs in HHT represent a model for end-stage liver disease (MELD) exception for transplantation [<a href="#rid113">113,115</a>]. (See  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.)</p><p>A 2006 series from the European Liver Transplant Registry reported outcomes in 40 individuals with HHT and severe liver disease who underwent liver transplantation [<a href="#rid117">117</a>]. Ten-year actuarial patient and graft survival rates were 82.5 percent. There were seven perioperative deaths, six due to bleeding and one due to heart failure, and one late death (at 11 years) due to chronic rejection. </p><p>Pulmonary involvement through portopulmonary hypertension is considered a transplant priority and proposed as a MELD exception [<a href="#rid126">126</a>]. Right-heart catheterization to evaluate the severity of pulmonary hypertension prior to transplant is advised [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H3647832702"><span class="h2">Cerebral lesions</span><span class="headingEndMark"> — </span>Lesions in the cerebral (or spinal) vasculature in individuals with HHT may include telangiectasia, AVMs, and aneurysms. These lesions result in varying degrees of hemorrhagic risk. They may also cause symptoms related to their size or location such as headache, focal neurologic deficit, or seizures; however, the majority of patients will have no complications from cerebral lesions.</p><p>Significant effort has been invested in trying to identify the patients at higher risk of future complications in whom the known risks of neurologic intervention are more justifiable. Most patients will never have a specific complication from their cerebral AVMs, but for others, the consequences of cerebral AVMs will lead to life-changing or life-limiting consequences.</p><p>For a small group of patients, symptoms may be used to indicate a higher likelihood of AVM presence, and an AVM that has already bled is usually treated. For highly symptomatic or ruptured cerebral AV shunts for which treatment is appropriate and feasible, therapeutic options include surgical excision, a number of endovascular techniques, or stereotactic radiotherapy. The risks associated with these interventions should not be underestimated [<a href="#rid127">127</a>]. The risk of rupture and details of therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1087.html" rel="external">"Brain arteriovenous malformations", section on 'Acute management issues'</a>.)</p><p>Management of cerebral lesions that have not bled is complex and should be performed by clinicians with expertise in this area who are aware of the results of the ARUBA (<strong>A</strong> <strong>R</strong>andomized trial of <strong>U</strong>nruptured <strong>B</strong>rain <strong>A</strong>VM therapy) trial [<a href="#rid128">128</a>]. The interpretation of this trial and its applicability to the HHT population has remained highly controversial, and in our experience, it is applied differently in Europe and the United States. Across the ERN, cerebral AVMs that have not bled are usually not treated [<a href="#rid129">129</a>]. A 2020 position statement on cerebral screening in HHT published by VASCERN suggested that data do not support routine intervention for unruptured AVMs, acknowledging the controversies that may arise and individual patients may have different preferences [<a href="#rid4">4</a>]. Some clinicians may weigh the risks and benefits differently.</p><p>The ARUBA trial randomly assigned individuals with a cerebral AVM (not knowingly HHT related) to receive or not to receive an interventional procedure (surgery, embolization, stereotactic radiotherapy) in addition to standard medical therapy [<a href="#rid128">128</a>]. The trial was halted early after accrual of 223 patients when the data and safety monitoring board noted a threefold increased risk of adverse outcomes in the intervention group. At a median follow-up of 33 months, the primary composite endpoint of death or symptomatic stroke was seen in 35 of 114 intervention patients (31 percent) versus 11 of 109 controls (10 percent). Individuals in the intervention group also had worse functional outcomes and a higher risk of hemorrhagic stroke. In a follow-up report that described an additional period of observation (mean follow-up of approximately 50 months total), there were 41 deaths or strokes in the intervention group and 15 deaths or strokes in the medical management group (incidence rate per 100 person-years, 12.3 versus 3.4, respectively) [<a href="#rid130">130</a>]. However, follow-up data were only available for one-half of the original participants.</p><p>There is no evidence that the risks associated with cerebral AVMs in HHT are higher or lower than the risks in non-HHT cerebral AVMs [<a href="#rid131">131</a>]. </p><p>There are other central nervous system vascular malformations that pose a very low risk of hemorrhage and usually no intervention is recommended. (See  <a class="medical medical_review" href="/z/d/html/1129.html" rel="external">"Vascular malformations of the central nervous system", section on 'Capillary telangiectasias'</a>.)</p><p>For the HHT patients with cerebral vascular malformations who do not fall into either of these groups, assessments of the risks and benefits of intervention are based on clinical judgment, which can be highly specific to the individual.</p><p class="headingAnchor" id="H592518635"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H2660960941"><span class="h2">Children</span><span class="headingEndMark"> — </span>Symptomatic children require specialist evaluation and treatment, as discussed in the sections above.</p><p>It is important that neurologic symptoms are promptly investigated and that parents with HHT are educated about the potential significance of these symptoms or clinical signs of cardiac failure/hydrovenous dysfunction in their children [<a href="#rid132">132</a>]. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Sites of large arteriovenous malformations'</a>.)</p><p>Screening of asymptomatic children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Children'</a>.)</p><p class="headingAnchor" id="H675231792"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Case reports have highlighted major complications of pregnancy in individuals with HHT. However, our series of 484 pregnancies in 199 individuals indicated that the vast majority are able to have a healthy pregnancy. This is an important observation since individuals with HHT are sometimes led to believe that pregnancy is too dangerous to undertake. That said, a small proportion did experience life-threatening complications, even in those who previously had only minor symptoms of HHT.</p><p>In this series, the following complications were noted [<a href="#rid133">133</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary arteriovenous malformation (PAVM) hemorrhage – 1.4 percent (95% CI 0.2-2.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Stroke – 1.2 percent (95% CI 0.3-2.2)</p><p class="bulletIndent1"><span class="glyph">●</span>Maternal deaths – 1.0 percent (95% CI 0.1-1.9)</p><p class="bulletIndent1"><span class="glyph">●</span>Myocardial infarction – 0.2 percent (one case)</p><p></p><p>General recommendations for the management of HHT during pregnancy include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk status</strong> – All pregnancies in women with HHT should be considered "high risk," and local obstetric services should be alerted to the need for greater than normal vigilance and pre-planning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Education</strong> – All individuals with HHT who become pregnant should receive written advice on pregnancy management; this is one of the European Reference Network (ERN) on Rare Multisystemic Vascular Diseases (VASCERN) HHT's five Outcome Measures defining good practice [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PAVMs</strong> – PAVMs will enlarge during pregnancy, and fatal hemorrhage from maternal PAVMs has been described [<a href="#rid133">133,134</a>]. As a result, individuals with HHT should be screened for PAVMs and treated maximally before pregnancy, although treatment may be safely undertaken in late pregnancy if required [<a href="#rid135">135</a>]. Hemoptysis of any degree or sudden severe dyspnea should be considered a medical emergency, prompting urgent hospitalization and institution of appropriate treatment. In the series described above, hemorrhages occurred in both treated and untreated patients, including four individuals who had previous PAVM embolization at four different institutions [<a href="#rid133">133</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other AVMs</strong> – Anecdotal data suggest that epistaxis may get worse and skin telangiectasia become more prominent during pregnancy; there are no firm data regarding effects on hepatic or cerebral AVMs. Screening for other types of AVMs in asymptomatic individuals is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Initial PAVM screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidural anesthesia</strong> – There is no evidence of hemorrhage from spinal AVMs in individuals with HHT who receive epidural anesthesia. Nevertheless, since spinal AVMs affect approximately 1 to 2 percent of HHT patients, some anesthetists will not perform epidural analgesia in HHT mothers unless magnetic resonance imaging (MRI) scans have excluded this possibility.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second stage of labor</strong> – Obstetricians advise that a prolonged second stage of labor should be avoided in individuals in whom cerebral AVMs have not been excluded. In some countries, it is assumed that cerebral AVMs may be present, and this advice is given to all individuals with HHT. In others, or if there would be specific separate recommendations were a cerebral AVM to be found, cerebral magnetic resonance imaging (MRI) is performed in pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic prophylaxis</strong> – In keeping with the general advice for patients with PAVMs and/or HHT, antibiotic prophylaxis should be provided during delivery [<a href="#rid75">75,107,136</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic counseling and testing</strong> – The patient should also be made aware that any offspring will have a 50 percent risk of inheriting HHT. Prenatal genetic testing is possible in families where the pathogenic variant has been identified in the family but is not necessary for proper pregnancy and delivery management [<a href="#rid129">129</a>]. Decisions about prenatal genetic testing are the choice of the parents, but discussion of all related issues is appropriate. The usual antenatal scans will be offered, and sonographers aware of the presence of HHT in the family will detect most major AVMs.</p><p></p><p class="headingAnchor" id="H2096516934"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>When managed by treatment of nosebleeds, iron deficiency anemia, and screening/treatment for pulmonary arteriovenous malformations (PAVMs), life expectancy in individuals with HHT is normal on a population basis [<a href="#rid137">137</a>].</p><p>However, in settings in which optimal management is not pursued on a nationwide basis, life expectancy is modestly reduced. For example, in a 2015 case-control series from a primary care database, 675 individuals with HHT demonstrated a three-year reduction in survival (median age of death of 77 years, compared with 80 years in 6696 age- and sex-matched controls) [<a href="#rid138">138</a>]. An important limitation was that the rates were overall survival rather than disease-specific survival. Causes of death could not be confirmed, but the most frequent serious complications included stroke and heart disease.</p><p>HHT can be life-limiting on an individual basis. Patients can die in childhood and young-adult life from HHT complications such as cerebral hemorrhage [<a href="#rid139">139,140</a>], pulmonary hemorrhage in pregnancy [<a href="#rid133">133</a>], and cerebral abscess from PAVMs [<a href="#rid88">88,141</a>]. Causes of death in older patients include sepsis and cardiac failure in studies from 2006 and 2018 that surveyed HHT patients asking for causes of death in their deceased relatives [<a href="#rid142">142,143</a>]. A reduced survival of 6.8 years in the affected parent compared with the non-affected parent was identified in the 2006 study, based on median age at death of 63.2 years (HHT parent) versus 70.0 years (non-HHT parent) [<a href="#rid143">143</a>]. Where HHT does contribute to death, the mean life expectancy reduction has been calculated at 19 years (based on 55 of 73 deceased patients selected because HHT was considered implicated in the cause of death) [<a href="#rid142">142</a>].</p><p>We interpret these data for the patient, stating that while HHT can result in early deaths (that medical care strives to reduce), overall life expectancy is surprisingly good in HHT and is increasing with improved medical care. The reason for the good survival figures is that deaths due to HHT seem to be balanced by protection conferred by HHT from common causes of death in the general population such as certain cancers and myocardial infarction [<a href="#rid137">137,144-147</a>].</p><p class="headingAnchor" id="H1879740289"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119057.html" rel="external">"Society guideline links: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a>.)</p><p class="headingAnchor" id="H955752164"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epistaxis</strong> – Epistaxis affects over 95 percent of individuals with hereditary hemorrhagic telangiectasia (HHT) and is the usual cause of iron deficiency anemia. Topical, systemic, and surgical treatments are available. We generally try to avoid toxicity of systemic therapies by using local preventive therapies (nasal humidification, ointments) and dietary changes; however, management is individualized. Expert otorhinological review and management is important and often the only additional treatment required. (See <a class="local">'Overview'</a> above and <a class="local">'Epistaxis'</a> above.)</p><p></p><p class="bulletIndent1">Rarely, patients may require systemic therapies such as <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>, <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a>, or <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> if epistaxis is recurrent or localized interventions are insufficient. For these individuals, we continue to suggest tamoxifen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Other options are reasonable and may be preferred due to their differing side effect profiles or patient preference. Systemic agents are generally avoided in individuals with prior venous thromboembolism (VTE) and should be used with caution if there are additional risk factors for VTE or arterial thromboembolism. (See <a class="local">'Bevacizumab and other systemic antiangiogenic therapies'</a> above and <a class="local">'Tamoxifen and other non-guideline approaches'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal lesions</strong> – Gastrointestinal lesions are present in up to 20 percent of patients but rarely require treatment. If bleeding occurs, local therapies may be administered endoscopically, but gastrointestinal bleeding requiring transfusions or iron administration is often due to multiple lesions and is treated with systemic agents rather than frequent endoscopic interventions. (See <a class="local">'Gastrointestinal lesions'</a> above and <a class="local">'Bevacizumab and other systemic antiangiogenic therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron deficiency</strong> – Iron deficiency and iron deficiency anemia are common, usually from epistaxis. Most individuals are treated with oral iron, but parenteral iron and/or blood transfusions may be required. (See <a class="local">'Iron deficiency and iron deficiency anemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary AVMs</strong> – Pulmonary arteriovenous malformations (PAVMs) are especially concerning because of potentially life-threatening cerebral complications including ischemic stroke caused by a paradoxical embolus to the brain or brain abscess caused by a paradoxical septic embolus or hypoxia. Bleeding leading to hemoptysis or hemothorax is much less common but can occur. (See <a class="local">'Pulmonary AVMs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We screen all adults with HHT for PAVMs. (See  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'PAVM screening'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For PAVMs of a size amenable to embolization, we use embolotherapy, unless there are complications such as significant pulmonary hypertension that require more individualized therapy. (See <a class="local">'Principles of PAVM management'</a> above and  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Patients suitable for embolotherapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antibiotic prophylaxis is required for all PAVM patients prior to dental and surgical procedures. PAVM management is discussed above and separately. (See <a class="local">'Principles of PAVM management'</a> above and  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic AVMs</strong> – Hepatic AVMs are usually asymptomatic but can require intense, informed specialist care. In our experience, one major risk is of misdiagnoses as metastases. Symptoms attributable to high-output heart failure (often indolent) are seen in &lt;10 percent of patients; acute presentations with portal hypertension and/or biliary disease are less common. For symptomatic liver involvement, initial treatment includes optimizing cardiac status, iron stores, and emergency management as needed. If intense medical management fails, liver transplantation is the treatment of choice. <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">Bevacizumab</a> may also be helpful for nontransplant candidates. (See <a class="local">'Hepatic AVMs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brain AVMs</strong> – Management of cerebral lesions is complex. Symptomatic lesions and lesions that have bled are managed by specialized units with neurology expertise. For nonsymptomatic patients, management is more challenging since the ARUBA (<strong>A</strong> <strong>R</strong>andomized trial of <strong>U</strong>nruptured <strong>B</strong>rain <strong>A</strong>VM therapy) trial indicated that intervention results in worse outcomes than expectant management in unselected cases. Expertise in this area is required for optimal management. (See <a class="local">'Cerebral lesions'</a> above and  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Cerebral AVM screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children and pregnancy</strong> – (See <a class="local">'Special populations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– Prognosis is variable. Most patients can expect very good life expectancy, and life expectancy continues to improve. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and routine screening</strong> – (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a> and  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs"</a>.)</p><p></p><p class="headingAnchor" id="H319002300"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Vijeya Ganesan, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Faughnan ME, Mager JJ, Hetts SW, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med 2020; 173:989.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Buscarini E, Sabbà C, et al. The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care. Eur J Med Genet 2022; 65:104370.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Buscarini E, Kjeldsen AD, et al. European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT). Orphanet J Rare Dis 2018; 13:136.</a></li><li><a class="nounderline abstract_t">Eker OF, Boccardi E, Sure U, et al. European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). Orphanet J Rare Dis 2020; 15:165.</a></li><li><a class="nounderline abstract_t">Müller-Hülsbeck S, Marques L, Maleux G, et al. CIRSE Standards of Practice on Diagnosis and Treatment of Pulmonary Arteriovenous Malformations. Cardiovasc Intervent Radiol 2020; 43:353.</a></li><li><a class="nounderline abstract_t">Anderson E, Sharma L, Alsafi A, Shovlin CL. Pulmonary arteriovenous malformations may be the only clinical criterion present in genetically confirmed hereditary haemorrhagic telangiectasia. Thorax 2022; 77:628.</a></li><li><a class="nounderline abstract_t">Dupuis-Girod S, Ambrun A, Decullier E, et al. Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial. JAMA 2016; 316:934.</a></li><li><a class="nounderline abstract_t">Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48:73.</a></li><li><a class="nounderline abstract_t">Buscarini E, Botella LM, Geisthoff U, et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 2019; 14:28.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Millar CM, Droege F, et al. Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 2019; 14:210.</a></li><li><a class="nounderline abstract_t">van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990; 335:953.</a></li><li><a class="nounderline abstract_t">Yaniv E, Preis M, Hadar T, et al. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009; 119:284.</a></li><li><a class="nounderline abstract_t">Yaniv E, Preis M, Shevro J, et al. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial. Rhinology 2011; 49:214.</a></li><li><a class="nounderline abstract_t">Gaillard S, Dupuis-Girod S, Boutitie F, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost 2014; 12:1494.</a></li><li><a class="nounderline abstract_t">Geisthoff UW, Seyfert UT, Kübler M, et al. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res 2014; 134:565.</a></li><li><a class="nounderline abstract_t">Mei-Zahav M, Gendler Y, Bruckheimer E, et al. Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Whitehead KJ, Sautter NB, McWilliams JP, et al. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. JAMA 2016; 316:943.</a></li><li><a class="nounderline abstract_t">Peterson AM, Lee JJ, Kallogjeri D, et al. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 2020; 146:1006.</a></li><li><a class="nounderline abstract_t">Dupuis-Girod S, Pitiot V, Bergerot C, et al. Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial. Sci Rep 2019; 9:11986.</a></li><li><a class="nounderline abstract_t">Dupuis-Girod S, Fargeton AE, Grobost V, et al. Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Khanwalkar AR, Rathor A, Read AK, et al. Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization. Int Forum Allergy Rhinol 2022; 12:1034.</a></li><li><a class="nounderline abstract_t">McWilliams JP, Majumdar S, Kim GH, et al. North American Study for the Treatment of Recurrent Epistaxis with Doxycycline: The NOSTRIL trial. J Thromb Haemost 2022; 20:1115.</a></li><li><a class="nounderline abstract_t">Livesey JA, Manning RA, Meek JH, et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax 2012; 67:328.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Chamali B, Santhirapala V, et al. Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets. PLoS One 2014; 9:e88812.</a></li><li><a class="nounderline abstract_t">Devlin HL, Hosman AE, Shovlin CL. Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. N Engl J Med 2013; 368:876.</a></li><li><a class="nounderline abstract_t">Yin LX, Reh DD, Hoag JB, et al. The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia. Laryngoscope 2016; 126:1029.</a></li><li><a class="nounderline abstract_t">Silva BM, Hosman AE, Devlin HL, Shovlin CL. Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia. Laryngoscope 2013; 123:1092.</a></li><li><a class="nounderline abstract_t">Hsu YP, Hsu CW, Bai CH, et al. Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis. Otolaryngol Head Neck Surg 2019; 160:22.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Sulaiman NL, Govani FS, et al. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 2007; 98:1031.</a></li><li><a class="nounderline abstract_t">Saba HI, Morelli GA, Logrono LA. Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994; 330:1789.</a></li><li><a class="nounderline abstract_t">Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol 1999; 13:319.</a></li><li><a class="nounderline abstract_t">Boyer H, Fernandes P, Le C, Yueh B. Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol 2015; 5:435.</a></li><li><a class="nounderline abstract_t">Woodard TD, Yappel-Sinkko KB, Wang X, et al. Sclerotherapy Versus Cautery/Laser Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia. Laryngoscope 2022; 132:920.</a></li><li><a class="nounderline abstract_t">Feller CN, Adams JA, Friedland DR, Poetker DM. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia. Am J Otolaryngol 2022; 43:103409.</a></li><li><a class="nounderline abstract_t">Dupuis-Girod S, Shovlin CL, Kjeldsen AD, et al. European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)? Eur J Med Genet 2022; 65:104575.</a></li><li><a class="nounderline abstract_t">Albitar HA, Almodallal Y, Nishimura R, Iyer VN. Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab. Mayo Clin Proc Innov Qual Outcomes 2020; 4:460.</a></li><li><a class="nounderline abstract_t">Dupuis-Girod S, Rivière S, Lavigne C, et al. Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial. J Intern Med 2023; 294:761.</a></li><li><a class="nounderline abstract_t">Guilhem A, Fargeton AE, Simon AC, et al. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients. PLoS One 2017; 12:e0188943.</a></li><li><a class="nounderline abstract_t">Iyer VN, Apala DR, Pannu BS, et al. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding. Mayo Clin Proc 2018; 93:155.</a></li><li><a class="nounderline abstract_t">Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med 2019; 285:223.</a></li><li><a class="nounderline abstract_t">Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012; 307:948.</a></li><li><a class="nounderline abstract_t">Vázquez C, Gonzalez ML, Ferraris A, et al. Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia. PLoS One 2020; 15:e0228486.</a></li><li><a class="nounderline abstract_t">Thompson AB, Ross DA, Berard P, et al. Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. Allergy Rhinol (Providence) 2014; 5:91.</a></li><li><a class="nounderline abstract_t">Chavan A, Schumann-Binarsch S, Schmuck B, et al. Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia. Am J Hematol 2017; 92:E641.</a></li><li><a class="nounderline abstract_t">Epperla N, Kapke JT, Karafin M, et al. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Am J Hematol 2016; 91:E313.</a></li><li><a class="nounderline abstract_t">Rosenberg T, Fialla AD, Kjeldsen J, Kjeldsen AD. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series. Rhinology 2019; 57:242.</a></li><li><a class="nounderline abstract_t">Al-Samkari H, Albitar HA, Olitsky SE, et al. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Haemophilia 2020; 26:1038.</a></li><li><a class="nounderline abstract_t">Al-Samkari H, Kasthuri RS, Parambil JG, et al. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica 2021; 106:2161.</a></li><li><a class="nounderline abstract_t">Gossage JR. The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia-Related Bleeding. Mayo Clin Proc 2018; 93:130.</a></li><li><a class="nounderline abstract_t">Hosman A, Westermann CJ, Snijder R, et al. Follow-up of Thalidomide treatment in patients with Hereditary Haemorrhagic Telangiectasia. Rhinology 2015; 53:340.</a></li><li><a class="nounderline abstract_t">Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007; 13:5979.</a></li><li><a class="nounderline abstract_t">Bowcock SJ, Patrick HE. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias? Br J Haematol 2009; 146:220.</a></li><li><a class="nounderline abstract_t">Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16:420.</a></li><li><a class="nounderline abstract_t">Harrison L, Kundra A, Jervis P. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. J Laryngol Otol 2018; 132:866.</a></li><li class="breakAll">http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2017/03/WC500224884.pdf (Accessed on March 08, 2018).</li><li class="breakAll">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2017/03/human_orphan_001929.jsp&amp;mid=WC0b01ac058001d12b (Accessed on March 14, 2018).</li><li><a class="nounderline abstract_t">Fang J, Chen X, Zhu B, et al. Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study. Otolaryngol Head Neck Surg 2017; 157:217.</a></li><li><a class="nounderline abstract_t">Parambil JG, Woodard TD, Koc ON. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2018; 128:2234.</a></li><li><a class="nounderline abstract_t">Faughnan ME, Gossage JR, Chakinala MM, et al. Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. Angiogenesis 2019; 22:145.</a></li><li><a class="nounderline abstract_t">Skaro AI, Marotta PJ, McAlister VC. Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia. Ann Intern Med 2006; 144:226.</a></li><li><a class="nounderline abstract_t">Wheatley-Price P, Shovlin C, Chao D. Interferon for metastatic renal cell cancer causing regression of hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2005; 39:344.</a></li><li><a class="nounderline abstract_t">Spiekerkoetter E, Tian X, Cai J, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 2013; 123:3600.</a></li><li><a class="nounderline abstract_t">Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24:203.</a></li><li><a class="nounderline abstract_t">Geisthoff UW, Nguyen HL, Röth A, Seyfert U. How to manage patients with hereditary haemorrhagic telangiectasia. Br J Haematol 2015; 171:443.</a></li><li><a class="nounderline abstract_t">Hitchings AE, Lennox PA, Lund VJ, Howard DJ. The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 2005; 19:75.</a></li><li><a class="nounderline abstract_t">Kühnel TS, Wagner BH, Schurr CP, Strutz J. Clinical strategy in hereditary hemorrhagic telangiectasia. Am J Rhinol 2005; 19:508.</a></li><li><a class="nounderline abstract_t">Bergler W, Sadick H, Gotte K, et al. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 2002; 111:222.</a></li><li><a class="nounderline abstract_t">Folz BJ, Tennie J, Lippert BM, Werner JA. Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease. Rhinology 2005; 43:40.</a></li><li><a class="nounderline abstract_t">Steineger J, Osnes T, Heimdal K, Dheyauldeen S. Long-term experience with intranasal bevacizumab therapy. Laryngoscope 2018; 128:2237.</a></li><li><a class="nounderline abstract_t">Lund VJ, Darby Y, Rimmer J, et al. Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young's procedure: a 22-year experience. Rhinology 2017; 55:135.</a></li><li><a class="nounderline abstract_t">Simonds J, Miller F, Mandel J, Davidson TM. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119:988.</a></li><li><a class="nounderline abstract_t">Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121:636.</a></li><li><a class="nounderline abstract_t">Elphick A, Shovlin CL. Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia. Laryngoscope 2014; 124:1521.</a></li><li><a class="nounderline abstract_t">Chamali B, Finnamore H, Manning R, et al. Dietary supplement use and nosebleeds in hereditary haemorrhagic telangiectasia - an observational study. Intractable Rare Dis Res 2016; 5:109.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Jackson JE, Bamford KB, et al. Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 2008; 63:259.</a></li><li class="breakAll">http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2010/06/WC500093985.pdf (Accessed on March 08, 2018).</li><li><a class="nounderline abstract_t">Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R, et al. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010; 103:525.</a></li><li><a class="nounderline abstract_t">de Gussem EM, Snijder RJ, Disch FJ, et al. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology 2009; 47:85.</a></li><li><a class="nounderline abstract_t">Parambil JG, Gossage JR, McCrae KR, et al. Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. Angiogenesis 2022; 25:87.</a></li><li><a class="nounderline abstract_t">Kroon S, Snijder RJ, Hosman AE, et al. Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study. Angiogenesis 2021; 24:379.</a></li><li><a class="nounderline abstract_t">Sargeant IR, Loizou LA, Rampton D, et al. Laser ablation of upper gastrointestinal vascular ectasias: long term results. Gut 1993; 34:470.</a></li><li><a class="nounderline abstract_t">Finnamore H, Le Couteur J, Hickson M, et al. Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency. PLoS One 2013; 8:e76516.</a></li><li><a class="nounderline abstract_t">Rizvi A, Macedo P, Babawale L, et al. Hemoglobin Is a Vital Determinant of Arterial Oxygen Content in Hypoxemic Patients with Pulmonary Arteriovenous Malformations. Ann Am Thorac Soc 2017; 14:903.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Patel T, Jackson JE. Embolisation of PAVMs reported to improve nosebleeds by a subgroup of patients with hereditary haemorrhagic telangiectasia. ERJ Open Res 2016; 2.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Gilson C, Busbridge M, et al. Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia? Laryngoscope 2016; 126:2468.</a></li><li><a class="nounderline abstract_t">Mollet IG, Patel D, Govani FS, et al. Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes. PLoS One 2016; 11:e0147990.</a></li><li><a class="nounderline abstract_t">Thielemans L, Layton DM, Shovlin CL. Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia. Haematologica 2019; 104:e127.</a></li><li><a class="nounderline abstract_t">Boother EJ, Brownlow S, Tighe HC, et al. Cerebral Abscess Associated With Odontogenic Bacteremias, Hypoxemia, and Iron Loading in Immunocompetent Patients With Right-to-Left Shunting Through Pulmonary Arteriovenous Malformations. Clin Infect Dis 2017; 65:595.</a></li><li><a class="nounderline abstract_t">Santhirapala V, Williams LC, Tighe HC, et al. Arterial oxygen content is precisely maintained by graded erythrocytotic responses in settings of high/normal serum iron levels, and predicts exercise capacity: an observational study of hypoxaemic patients with pulmonary arteriovenous malformations. PLoS One 2014; 9:e90777.</a></li><li><a class="nounderline abstract_t">Ahmedzai S, Balfour-Lynn IM, Bewick T, et al. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 2011; 66 Suppl 1:i1.</a></li><li><a class="nounderline abstract_t">Gawecki F, Strangeways T, Amin A, et al. Exercise capacity reflects airflow limitation rather than hypoxaemia in patients with pulmonary arteriovenous malformations. QJM 2019; 112:335.</a></li><li><a class="nounderline abstract_t">Gawecki F, Myers J, Shovlin CL. Veterans Specific Activity Questionnaire (VSAQ): a new and efficient method of assessing exercise capacity in patients with pulmonary arteriovenous malformations. BMJ Open Respir Res 2019; 6:e000351.</a></li><li><a class="nounderline abstract_t">Mason CG, Shovlin CL. Flight-related complications are infrequent in patients with hereditary haemorrhagic telangiectasia/pulmonary arteriovenous malformations, despite low oxygen saturations and anaemia. Thorax 2012; 67:80.</a></li><li><a class="nounderline abstract_t">Fatania G, Gilson C, Glover A, et al. Uptake and radiological findings of screening cerebral magnetic resonance scans in patients with hereditary haemorrhagic telangiectasia. Intractable Rare Dis Res 2018; 7:236.</a></li><li><a class="nounderline abstract_t">Brinjikji W, Nasr DM, Wood CP, Iyer VN. Pulmonary Arteriovenous Malformations Are Associated with Silent Brain Infarcts in Hereditary Hemorrhagic Telangiectasia Patients. Cerebrovasc Dis 2017; 44:179.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Condliffe R, Donaldson JW, et al. British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations. Thorax 2017; 72:1154.</a></li><li><a class="nounderline abstract_t">Shovlin C, Bamford K, Sabbà C, et al. Prevention of serious infections in hereditary hemorrhagic telangiectasia: roles for prophylactic antibiotics, the pulmonary capillaries-but not vaccination. Haematologica 2019; 104:e85.</a></li><li><a class="nounderline abstract_t">Lacombe P, Lacout A, Marcy PY, et al. Diagnosis and treatment of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: An overview. Diagn Interv Imaging 2013; 94:835.</a></li><li><a class="nounderline abstract_t">Gill SS, Roddie ME, Shovlin CL, Jackson JE. Pulmonary arteriovenous malformations and their mimics. Clin Radiol 2015; 70:96.</a></li><li><a class="nounderline abstract_t">Woodward CS, Pyeritz RE, Chittams JL, Trerotola SO. Treated pulmonary arteriovenous malformations: patterns of persistence and associated retreatment success. Radiology 2013; 269:919.</a></li><li><a class="nounderline abstract_t">Hsu CC, Kwan GN, Evans-Barns H, van Driel ML. Embolisation for pulmonary arteriovenous malformation. Cochrane Database Syst Rev 2018; 1:CD008017.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Gibbs JS, Jackson JE. Management of pulmonary arteriovenous malformations in pulmonary hypertensive patients: a pressure to embolise? Eur Respir Rev 2009; 18:4.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Tighe HC, Davies RJ, et al. Embolisation of pulmonary arteriovenous malformations: no consistent effect on pulmonary artery pressure. Eur Respir J 2008; 32:162.</a></li><li><a class="nounderline abstract_t">Alsafi A, Jackson JE, Fatania G, et al. Patients with in-situ metallic coils and Amplatzer vascular plugs used to treat pulmonary arteriovenous malformations since 1984 can safely undergo magnetic resonance imaging. Br J Radiol 2019; 92:20180752.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Buscarini E, Hughes JMB, et al. Long-term outcomes of patients with pulmonary arteriovenous malformations considered for lung transplantation, compared with similarly hypoxaemic cohorts. BMJ Open Respir Res 2017; 4:e000198.</a></li><li class="breakAll">https://www.gov.uk/government/publications/the-never-events-list-for-2012-13.</li><li><a class="nounderline abstract_t">Shovlin C, Bamford K, Wray D. Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia. Br Dent J 2008; 205:531.</a></li><li><a class="nounderline abstract_t">Revuz S, Decullier E, Ginon I, et al. Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability. PLoS One 2017; 12:e0184227.</a></li><li><a class="nounderline abstract_t">Vorselaars V, Velthuis S, van Gent M, et al. Pulmonary Hypertension in a Large Cohort with Hereditary Hemorrhagic Telangiectasia. Respiration 2017; 94:242.</a></li><li><a class="nounderline abstract_t">Letteboer TG, Mager JJ, Snijder RJ, et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 2006; 43:371.</a></li><li><a class="nounderline abstract_t">Lesca G, Olivieri C, Burnichon N, et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med 2007; 9:14.</a></li><li><a class="nounderline abstract_t">Buscarini E, Leandro G, Conte D, et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci 2011; 56:2166.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="0f6a6e7c63606969666c6a4f6a6e7c63606969666c6a216a7a">[email protected]</span>. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64:179.</a></li><li class="breakAll">https://vascern.eu/wp-content/uploads/2018/03/Hepatic-AVM-Workshop-2017.pdf (Accessed on August 30, 2019).</li><li><a class="nounderline abstract_t">Andrejecsk JW, Hosman AE, Botella LM, et al. Executive summary of the 12th HHT international scientific conference. Angiogenesis 2018; 21:169.</a></li><li><a class="nounderline abstract_t">Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.</a></li><li><a class="nounderline abstract_t">Lerut J, Orlando G, Adam R, et al. Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European liver transplant registry. Ann Surg 2006; 244:854.</a></li><li><a class="nounderline abstract_t">Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006; 85:631.</a></li><li><a class="nounderline abstract_t">Mitchell A, Adams LA, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008; 14:210.</a></li><li><a class="nounderline abstract_t">Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 361:931; author reply 931.</a></li><li><a class="nounderline abstract_t">Olsen LB, Kjeldsen AD, Poulsen MK, et al. High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment. Orphanet J Rare Dis 2020; 15:334.</a></li><li><a class="nounderline abstract_t">Maestraggi Q, Bouattour M, Toquet S, et al. Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report. Medicine (Baltimore) 2015; 94:e1966.</a></li><li><a class="nounderline abstract_t">DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49:1729.</a></li><li><a class="nounderline abstract_t">Boillot O, Bianco F, Viale JP, et al. Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement. Gastroenterology 1999; 116:187.</a></li><li><a class="nounderline abstract_t">Dupuis-Girod S, Chesnais AL, Ginon I, et al. Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study. Liver Transpl 2010; 16:340.</a></li><li><a class="nounderline abstract_t">Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol 2013; 59:367.</a></li><li class="breakAll">http://www.arubastudy.org/ (Accessed on August 30, 2012).</li><li><a class="nounderline abstract_t">Mohr JP, Parides MK, Stapf C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 2014; 383:614.</a></li><li class="breakAll">https://www.orpha.net/consor/www/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=774 (Accessed on August 28, 2019).</li><li><a class="nounderline abstract_t">Mohr JP, Overbey JR, Hartmann A, et al. Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial. Lancet Neurol 2020; 19:573.</a></li><li><a class="nounderline abstract_t">Yang W, Liu A, Hung AL, et al. Lower risk of intracranial arteriovenous malformation hemorrhage in patients with hereditary hemorrhagic telangiectasia. Neurosurgery 2016; 78:684.</a></li><li><a class="nounderline abstract_t">Ganesan V, Robertson F, Berg J. Neurovascular screening in hereditary haemorrhagic telangiectasia: dilemmas for the paediatric neuroscience community. Dev Med Child Neurol 2013; 55:405.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Sodhi V, McCarthy A, et al. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services. BJOG 2008; 115:1108.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Winstock AR, Peters AM, et al. Medical complications of pregnancy in hereditary haemorrhagic telangiectasia. QJM 1995; 88:879.</a></li><li><a class="nounderline abstract_t">Gershon AS, Faughnan ME, Chon KS, et al. Transcatheter embolotherapy of maternal pulmonary arteriovenous malformations during pregnancy. Chest 2001; 119:470.</a></li><li><a class="nounderline abstract_t">Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004; 169:994.</a></li><li><a class="nounderline abstract_t">Kjeldsen A, Aagaard KS, Tørring PM, et al. 20-year follow-up study of Danish HHT patients-survival and causes of death. Orphanet J Rare Dis 2016; 11:157.</a></li><li><a class="nounderline abstract_t">Donaldson JW, McKeever TM, Hall IP, et al. Complications and mortality in hereditary hemorrhagic telangiectasia: A population-based study. Neurology 2015; 84:1886.</a></li><li><a class="nounderline abstract_t">Krings T, Ozanne A, Chng SM, et al. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology 2005; 47:711.</a></li><li><a class="nounderline abstract_t">Kim H, Nelson J, Krings T, et al. Hemorrhage rates from brain arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. Stroke 2015; 46:1362.</a></li><li><a class="nounderline abstract_t">Kjeldsen AD, Tørring PM, Nissen H, Andersen PE. Cerebral abscesses among Danish patients with hereditary haemorrhagic telangiectasia. Acta Neurol Scand 2014; 129:192.</a></li><li><a class="nounderline abstract_t">Droege F, Thangavelu K, Stuck BA, et al. Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia. Vasc Med 2018; 23:377.</a></li><li><a class="nounderline abstract_t">Sabbà C, Pasculli G, Suppressa P, et al. Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM 2006; 99:327.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Awan I, Cahilog Z, et al. Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction. Int J Cardiol 2016; 215:179.</a></li><li><a class="nounderline abstract_t">Hosman AE, Devlin HL, Silva BM, Shovlin CL. Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis 2013; 8:195.</a></li><li><a class="nounderline abstract_t">Duarte CW, Black AW, Lucas FL, Vary CP. Cancer incidence in patients with hereditary hemorrhagic telangiectasia. J Cancer Res Clin Oncol 2017; 143:209.</a></li><li><a class="nounderline abstract_t">Hosman AE, Shovlin CL. Cancer and hereditary haemorrhagic telangiectasia. J Cancer Res Clin Oncol 2017; 143:369.</a></li></ol></div><div id="topicVersionRevision">Topic 109902 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32894695" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34737116" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30111344" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32600364" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31875234" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : CIRSE Standards of Practice on Diagnosis and Treatment of Pulmonary Arteriovenous Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35165143" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pulmonary arteriovenous malformations may be the only clinical criterion present in genetically confirmed hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27599328" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19553198" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30717761" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31462308" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1970032" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160429" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21743879" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25040799" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25005464" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32998220" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27599329" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32940653" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31427745" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32357559" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34989143" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35108451" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : North American Study for the Treatment of Recurrent Epistaxis with Doxycycline: The NOSTRIL trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22169361" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24586400" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23445111" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26393959" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23404156" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30200816" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000608" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8190155" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10485021" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25643928" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34160081" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Sclerotherapy Versus Cautery/Laser Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35216850" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35940549" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32793873" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37592715" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29190827" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29395350" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30191646" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22396517" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32032395" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25199101" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28776732" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26994402" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30907391" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32432841" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32675221" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29395348" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia-Related Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26735132" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Follow-up of Thalidomide treatment in patients with Hereditary Haemorrhagic Telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18023086" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438503" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20364125" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30191780" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30191780" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30191780" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28418273" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29451965" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30191360" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461979" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15758631" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Interferon for metastatic renal cell cancer causing regression of hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23867624" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20870325" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26205234" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : How to manage patients with hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15794079" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16270607" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical strategy in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11913682" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15844501" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29469958" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term experience with intranasal bevacizumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28064338" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young's procedure: a 22-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19194865" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21344445" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24458873" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27195194" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Dietary supplement use and nosebleeds in hereditary haemorrhagic telangiectasia - an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981912" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981912" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20135064" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19382502" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292451" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33211216" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491392" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Laser ablation of upper gastrointestinal vascular ectasias: long term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24146883" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28267932" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Hemoglobin Is a Vital Determinant of Arterial Oxygen Content in Hypoxemic Patients with Pulmonary Arteriovenous Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27730189" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Embolisation of PAVMs reported to improve nosebleeds by a subgroup of patients with hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27107394" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26866805" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30337360" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28430880" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cerebral Abscess Associated With Odontogenic Bacteremias, Hypoxemia, and Iron Loading in Immunocompetent Patients With Right-to-Left Shunting Through Pulmonary Arteriovenous Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24637882" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Arterial oxygen content is precisely maintained by graded erythrocytotic responses in settings of high/normal serum iron levels, and predicts exercise capacity: an observational study of hypoxaemic patients with pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21856702" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30657990" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Exercise capacity reflects airflow limitation rather than hypoxaemia in patients with pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30956797" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Veterans Specific Activity Questionnaire (VSAQ): a new and efficient method of assessing exercise capacity in patients with pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21953065" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Flight-related complications are infrequent in patients with hereditary haemorrhagic telangiectasia/pulmonary arteriovenous malformations, despite low oxygen saturations and anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30560015" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Uptake and radiological findings of screening cerebral magnetic resonance scans in patients with hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28746925" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Pulmonary Arteriovenous Malformations Are Associated with Silent Brain Infarcts in Hereditary Hemorrhagic Telangiectasia Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141890" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30705116" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prevention of serious infections in hereditary hemorrhagic telangiectasia: roles for prophylactic antibiotics, the pulmonary capillaries-but not vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23763987" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Diagnosis and treatment of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: An overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25443645" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pulmonary arteriovenous malformations and their mimics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23912618" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Treated pulmonary arteriovenous malformations: patterns of persistence and associated retreatment success.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29298459" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Embolisation for pulmonary arteriovenous malformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956115" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Management of pulmonary arteriovenous malformations in pulmonary hypertensive patients: a pressure to embolise?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385173" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Embolisation of pulmonary arteriovenous malformations: no consistent effect on pulmonary artery pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30894022" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Patients with in-situ metallic coils and Amplatzer vascular plugs used to treat pulmonary arteriovenous malformations since 1984 can safely undergo magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29071074" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Long-term outcomes of patients with pulmonary arteriovenous malformations considered for lung transplantation, compared with similarly hypoxaemic cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29071074" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Long-term outcomes of patients with pulmonary arteriovenous malformations considered for lung transplantation, compared with similarly hypoxaemic cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19023305" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28981519" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28743113" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Pulmonary Hypertension in a Large Cohort with Hereditary Hemorrhagic Telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16155196" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224686" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21290179" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26516032" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : EASL Clinical Practice Guidelines: Vascular diseases of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26516032" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : EASL Clinical Practice Guidelines: Vascular diseases of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29147802" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Executive summary of the 12th HHT international scientific conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18799522" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17122610" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European liver transplant registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16807748" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18236396" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19710496" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : More on bevacizumab in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33243256" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26579805" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19399912" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Vascular disorders of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869617" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20209594" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23557870" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23557870" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24268105" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24268105" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32562682" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26540357" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Lower risk of intracranial arteriovenous malformation hemorrhage in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23020298" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Neurovascular screening in hereditary haemorrhagic telangiectasia: dilemmas for the paediatric neuroscience community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18518871" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8593547" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Medical complications of pregnancy in hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11171725" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Transcatheter embolotherapy of maternal pulmonary arteriovenous malformations during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742303" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27876060" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : 20-year follow-up study of Danish HHT patients-survival and causes of death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25862798" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Complications and mortality in hereditary hemorrhagic telangiectasia: A population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16136265" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25858236" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Hemorrhage rates from brain arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23962120" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Cerebral abscesses among Danish patients with hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29781402" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16595564" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Life expectancy in patients with hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116331" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24354965" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27638773" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Cancer incidence in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27837281" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Cancer and hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
